3244 | Vojtech Huser | National Library of Medicine/NIH | Identification of Research Common Data Elements in HIV/AIDS using data science methods | AbbVie, Pfizer |
3246 | Dawn Farrell | Institute of Technology Tralee | Cochrane Review: Interventions for fatigue in inflammatory bowel disease | AbbVie |
3270 | Mirjana Stanic Benic | University Hospital Centre Rijeka | The impact of biological interventions on health‐related quality of life in adults with Crohn's disease | AbbVie, Biogen |
3287 | Robert Alexander | Takeda | Identification of biomarkers associated with specific sleep variables | GlaxoSmithKline |
3288 | Marc-Antoine Sparfel | Tours Hospital | MIDRA: influence of demographic and environmental factors on anti-tumor necrosis factor efficacy in rheumatoid arthritis a systematic review and meta-analysis of randomized controlled trials | AbbVie, Pfizer, UCB |
3320 | John Frew | Rockefeller University | Analysis of Outcome Measures in Hidradenitis Suppurativa | AbbVie |
3321 | Ewa Olech | IQVIA | Study of entry variables to optimize lupus trial design | GlaxoSmithKline |
3328 | Klaus Gottlieb | Eli Lilly USA | Mapping of components of the complete blood count and comprehensive metabolic profile to disease-specific clinical and endoscopy endpoints in phase 2 and 3 clinical trials of ulcerative colitis and Crohn’s disease | Takeda |
3361 | Gustav Nilsonne | Karolinska Institutet | Distribution of interleukin -6 in human plasma implications for statistical modelling and meta-analysis | AbbVie, GlaxoSmithKline |
3369 | Michael Ward
| NIH | Predicting Treatment Response to Tumor Necrosis Factor Inhibitors in Patients with Ankylosing Spondylitis | AbbVie, Pfizer |
3762 | Lin Wang | Johns Hopkins Hospital | The relative efficacy and safety of apalutamide, enzalutamide, abiraterone, and darolutamide for nonmetastatic castration-resistant prostate cancer
| Pfizer, Project Data Sphere |
3876 | Changyu Shen | Beth Israel Deaconess Medical Center | Risk and Benefit Stratification of Treatment Effects in Patients with Atrial Fibrillation | Boehringer Ingelheim, Daiichi Sankyo |
4036 | Akira Kimata | University of Tsukuba | Optimal interruption time of dabigatran per OS to Ablation (O-A time) in patients with atrial fibrillation Integrated analysis of 2 randomized controlled clinical trials | Boehringer Ingelheim
|
4037 | Karl Peace | Georgia Southern University | Assessment of Matching Methods for Causal Analysis
| Boehringer Ingelheim
|
4039 | Claire Daien | CHU lapeyronie | The most appropriate conventional DMARD to combine with tofacitinib in Rheumatoid Arthritis post hoc analysis of ORAL sync study | Pfizer |
4041 | Vivek Rudrapatna | University of California, San Francisco | Enhancing inference from real-world data using externally-derived missing data models: a pilot study of Ulcerative Colitis | AbbVie, Johnson & Johnson, Takeda |
4043 | Janneke van der Woude | Erasmus Medical Center | Effect of treatment on lipid profiles in patients with inflammatory bowel disease a systematic review and meta-analysis | Pfizer |
4047 | Miriam Oron
| Skintelligence ltd. | Test the prospects of expending the Skintelligence algorithm for predicting response to treatment with Alefacept and Ustekinumab in psoriatic patients affected with type I diabetes | ImmPort |
4113 | Lesley Inker | Tufts Medical Center | Chronic Kidney Disease Epidemiology – Clinical Trials Consortium (CKD-EPI CT) | GlaxoSmithKline, Takeda |
4115 | Amir Mahabadi | University Hospital Essen, West German Heart and Vascular Center | Impact of statin therapy on coronary artery calcification volume and density - A meta-analysis of randomized controlled trials | Pfizer |
4116 | Sharon Strauss | St. Michael’s Hospital | Comparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia a systematic review and individual patient data network meta-analysis | AbbVie |
4117 | John Frew | Rockefeller University | Predictors of Treatment Response, Adverse Events, Changes in Anaemia status and Assessment of Lesion Count Variability in Hidradenitis Suppurativa | AbbVie |
4118 | J. David Spence | Western University | On-Treatment analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial
| Pfizer |
4120 | Merryn Voysey | University of Oxford | The immunogenicity and sero-efficacy of pneumococcal vaccines | Pfizer |
4121 | Frederikus Klok | Leiden University Medical Center | Performance of the AF-adapted VTE-BLEED score for predicting major bleeding in patients with atrial fibrillation a post-hoc analysis of the ENGAGE-AF TIMI-48 Study | Daiichi Sankyo |
4275 | Lisa Stamp | University of Otago | Serum urate as a biomarker in gout Protocol for individual patient data analysis for OMERACT 2020
| Takeda |
4278 | Jennifer Quint | Imperial College London | Withdrawing inhaled corticosteroid (ICS) treatment in people with COPD a real world study
| Boehringer Ingelheim |
4316 | Martin Okun | Fort HealthCare | Geospatial and Seasonal Variation in Psoriasis Severity Analysis of Placebo Response Data from Phase 3 placebo-controlled trials in moderate-severe psoriasis | AbbVie |
4319 | Maria Alice Franzoi | Jules Bordet Institut | Clinical implications of body mass index and weight in metastatic breast cancer patients receiving abemaciclib. A combined individual patient level data sub-analysis of MONARCH 2 and MONARCH 3 trials. | Lilly |
4324 | Peng Xie | Chongqing Medical University | Comparative efficacy and tolerability of new-generation antidepressants for major depressive disorder in children and adolescents: protocol of an individual patient data meta-analys | GlaxoSmithKline, Lilly, Pfizer |
4326 | John Markman | University of Rochester | Phenotypic Characterization of Chronic Neuropathic Pain Following Post-Traumatic and Post-Surgical Injury | Pfizer |
4327 | Michael Szarek | SUNY Downstate Medical Center | Analysis of Total Events and Hospitalizations in the SPARCL Study | Pfizer |
4329, 4048 | Shomron Ben-Horin | Sun Yatsen 1st affiliated Hospital | Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease | AbbVie, Biogen, Johnson & Johnson, Takeda, UCB |
4330 | Laure Gossec | Sorbonne Université | Domains of health important for Rheumatoid Arthritis patients can be assessed separately: Reliability and Responsiveness of the Rheumatoid Arthritis Impact of Disease Score - 7 items (RAID.7i) | Pfizer |
4352 | Stefano Barco | University Medical Center Mainz | Differential effects of long-term treatment with warfarin vs. edoxaban on blood count parameters. A parallel posthoc analysis of the Hokusai VTE and Engage AF-TIMI-48 trials | Daiichi Sankyo |
4540 | Chris Gale | University of Leeds | Efficacy and safety of edoxaban versus warfarin in patients with atrial fibrillation and frailty insights from the ENGAGE AF-TIMI 48 trial | Daiichi Sankyo |
4541 | C Elizabeth Caldon | Garvan Institute of Medical Research | Therapeutic targeting of dual CDK4/6 inhibitor and endocrine resistant breast cancer | Pfizer |
4913 | Susan Halabi | Duke University | Surrogate Endpoints of Overall Survival in Non-Metastatic Renal Clear Cell Carcinoma | Pfizer, Project Data Sphere |
4915 | Rachel Tomko | Medical University of South Carolina | Predicting Individuals' Probability of Response to Smoking Cessation Pharmacotherapy | Pfizer |
4917 | Andrea Cipriani | University of Oxford | Choosing the Right Antidepressant for Depressive Disorder in Adults: Individual Patient Data Network Meta-Analysis | GlaxoSmithKline, Lilly, Lundbeck |
4918 | Nina Hilkens | Radboudmc Nijmegen | Association between blood pressure, blood pressure variability and the risk of post-stroke dementia | Boehringer Ingelheim |
4919 | Hendrik Jan Guchelaar | Leiden University Medical Center (LUMC) | Effect of digoxin on survival outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors | Pfizer |
4920 | Gustavo Turecki | Douglas Mental Health University Institute | Predicting Treatment Efficacy in Individuals with Major Depression -- Deep Neural Networks for Physiological Patient Parameters
| Pfizer |
4921 | Tim Brümmendorf | University Hospital Aachen | Entropy based Biomarkers for individualized response on Bosutinib treatment in chronic phase CML | Pfizer |
4922, 3274 | Diane van der Woude | Leiden University Medical Center | Effect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis | AbbVie, Pfizer |
4926 | Eva-Maria Gamper | Medical University Innsbruck | Comparison of the EORTC QLU-C10D with generic utility instruments and development of a comprehensive manual for its use | Boehringer Ingelheim |
4931 | Siddharth Singh | University of California, San Diego | Early changes in inflammatory biomarkers and long-term outcomes in patients with IBD: A pooled post-hoc analyses of clinical trials | AbbVie, Takeda |
4933 | Hongxia Wang | Shanghai Jiao Tong University School of Medicine | Novel predictive biomarker for therapeutic sensitivity of CKD4/6 inhibitor in breast cancer patients | Pfizer |
4949, 3190 | Vivek Rudrapatna | University of California San Francisco | Efficacy of Crohn’s Disease Treatment Stratified by Disease Phenotype | AbbVie, Biogen, Johnson & Johnson, Takeda, UCB |
4950 | John “Devin” Peipert | Northwestern University | Justification of PROMIS (FACIT) Fatigue Short Form 10a scale for FDA Drug Development ToolQualification in Rheumatoid Arthritis | AbbVie |
5073 | Philip Robinson | University of Queensland | Assessment of treatment outcome using ASAS40 with etanercept in non-radiographic axSpA by baseline CRP - a re-analysis of trial data | Pfizer |
5074 | Sebastian Zundler | University Hospital Erlangen | Evaluation of the relationship between vedolizumab peripheral blood serum level at week 6 and binary clinical outcomes at week 10/14 - a meta-analysis | Takeda |
5079 | Maureen Dubreuil | Boston University | Clinical and MRI predictors of Clinical Response in Axial Spondyloarthritis | AbbVie |
5080 | Joel Skaistis | Beaumont Health | Benefit of Anticoagulation in Cryptogenic Stroke According to Biomarker Level | Boehringer Ingelheim |
5086 | Junko Takeshita | University of Pennsylvania | A Systematic Review to Describe the Demographic Diversity of Dermatologic Clinical Trial Participants for Common Dermatologic Diseases | AbbVie, Lilly, Regeneron |
5095 | Mathilde Nijkeuter | University Medical Center Utrecht | Assessing bleeding risk in patients with cancer-associated thrombosis | Daiichi Sankyo |
5096 | Joo Sang Lee | Samsung Medical Center, South Korea | Harnessing genetic interactions to advance precision cancer medicine | Tempus AI, Inc. |
5098 | Christopher Baethge | University of Cologne Medical School | Dose-response relationships in antidepressant pharmacotherapy of depressive disorders with (S)SNRI: a systematic review and meta-analysis | Lilly |
5099 | Jorge Hernando | Vall d ́Hebron University Hospital | Impact of gender on multikinase inhibitors (MKIs) toxicity in patients (pts) with advanced pancreatic and gastrointestinal neuroendocrine tumors (NETs) | Pfizer |
5163 | Susan Bates | Columbia University Medical Center | Assessing the tumor growth and decay rates in patients with pancreatic cancer treated with Gemcitabine/Abraxane: Comparing real world data with clinical trial data | Celgene Corporation |
5165 | Byeongzu Ghang | Jeju National University Hospital | Reanalysis of CARES study to investigate the incidence of cardiovascular events and death after initiation and discontinuation of allopurinol and febuxostat
| Takeda |
5166 | Thomas Metkus | Johns Hopkins University School of Medicine | Severe sepsis in the cardiac intensive care unit: management strategies and outcomes | Lilly |
5207 | Fasihul Khan | University of Nottingham | A systematic review and individual patient data meta-analysis of physiological biomarkers in idiopathic pulmonary fibrosis | BioLINCC, Boehringer Ingelheim, Johnson & Johnson, Roche |
5209 | Bruce Perkins | University of Toronto | TRIAL-INFORMED DKA MITIGATION EDUCATIONAL TOOL | Boehringer Ingelheim |
5276 | Yan Luo | Kyoto University | Predicting the Treatment Response of Certolizumab for Individual Patients with Rheumatoid Arthritis: An Individual Participant Data Meta-Analysis | UCB |
5290 | Ashley Hopkins | Flinders University | Predictors of therapeutic and adverse effects of medicines used in the treatment of gastrointestinal cancers | Boehringer Ingelheim, GlaxoSmithKline, Lilly, Roche |
5291 | Sarah Nevitt | University of Liverpool | Antiepileptic drug monotherapy for epilepsy: an updated Cochrane review and individual participant data network meta-analysis | UCB |
5292 | Désirée van der Heijde | Leiden University Medical Center | Measurement properties of the instruments used in the outcome assessment of axial spondyloarthritis | UCB |
5294 | Daniel Caldeira | University of Lisbon/CCUL | The clinical impact of dabigratran in patients with non-valvular atrial fibrillation who had a fall or head injury: a retrospective analysis of RE-LY | Boehringer Ingelheim |
5325, 5324 | Daniel Goldenholz | Beth Israel Deaconess Medical Center | Retrospective analysis of placebo arm data in clinical epilepsy trials | GlaxoSmithKline, UCB |
5330 | Laura Bonnett | University of Liverpool | Modelling seizure rates rather than time to an event within clinical trials of antiepileptic drugs | UCB |
5352 | Elena Myasoedova | Mayo Clinic | Individualized Prediction of Treatment Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning Approach
| Roche, UCB |
5435 | Matthew Gilbert | University of Vermont | Effect of Albiglutide on Cardiovascular Outcomes in Older Adults with Type 2 Diabetes: a Post Hoc Analysis of a Randomized Controlled Trial | GlaxoSmithKline |
5436 | Adrian Wagg | University of Alberta | A pooled analysis of the efficacy and tolerability of tolterodine for the treatment of Overactive Bladder (OAB) in patients over the age of 65 years of age | Pfizer |
5456 | Ramona Belfiore-Oshan | Critical Path Institute | Validation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy | CureDuchenne |
5483 | David McAllister | University of Glasgow | Assessing heterogeneity in relative treatment efficacy by age, sex and comorbidity. | Boehringer Ingelheim, Lilly, Roche, Takeda, UCB |
5567 | Neeraj Narula | McMaster University | Impact of Ulcer Size and Extent of Inflammation On Ability To Achieve Endoscopic Healing In Crohns Disease: An EXTEND Post-Hoc Analysis | AbbVie |
5812 | Yougen Wu | The Fifth People's Hospital of Shanghai, Fudan University | Development and validation of nomograms for predicting efficacy and toxicity in cancer patients treated with immune checkpoint inhibitors | Roche |
5813 | Phillip Garfin | Seattle Genetics Inc. | Effectiveness of cytotoxic chemotherapy for the treatment metastatic breast cancer subtypes | Roche |
5852 | Marliese Alexander | Peter MacCallum Cancer Centre | Infective outcomes in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: an individual patient data meta-analysis | Roche |
5853 | Florian Naudet | CHU Rennes | Data-sharing and re-analysis for main studies assessed by the European Medicines Agency - a cross-sectional study on European Public Assessment Reports | AbbVie |
5869 | Alexandra Freeman | University of Cambridge | Meta-analysis of the adverse effects of trastuzumab in women with breast cancer | Roche |
5871 | Nobuhisa Kanahara | Chiba University Center for Forensic Mental Health | Determination of dopamine supersensitivity psychosis in randomized controlled studies of long-acting injectable vs. oral agents of the same atypical antipsychotic in schizophrenia subjects | Lilly |
5872 | Yaw Nyame | University of Washington Medical Center | Representation of Low-Grade Prostate Cancer in Metastatic Prostate Cancer Trials | Pfizer |
5880 | Benjamin Schneider | Iowa State University | Optimal Scheduling of First-Line Therapeutics in Non-Small Cell Lung Cancer | Lilly, Roche |
5894 | Takashi Sozu | Tokyo University of Science | Matrix Decomposition in Meta-Analysis for Extraction of Adverse Event Pattern and Patient-Level Safety Profile | Lilly |
5897 | John Peipert | Northwestern University | Justification of PROMIS (FACIT) Fatigue Short Form 10a scale for FDA Drug Development Tool Qualification in Rheumatoid Arthritis | Pfizer |
5901 | Junhao Hu | Chinese Academy of Science | Vessel pericytes NO-sGC signaling in COVID-19 | Hannover Medical School |
5902 | Thrasyvoulos Tzellos | Norland University Hospital | Development and validation of a IHS4 dichotomous outcome for assessing anti-inflammatory treatment efficacy for the treatment of hidradenitis suppurativa | AbbVie |
5904 | Saskia Middeldorp | Amsterdam UMC | Hokusai post VTE study: long-term outcome after heparin plus edoxaban versus heparin plus vitamin K antagonists for acute deep vein thrombosis and pulmonary embolism | Daiichi Sankyo |
5921 | Paul Schulz | University of Texas Health Science Center | Identification of biomarkers associated with Alzheimer’s disease progression that correlate with responses to medications | Lilly |
5924 | Iris Sommer | University Medical Center Groningen | Meta-analysis of efficacy of cholinesterase inhibitors on individual neuropsychiatric symptoms in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies | AbbVie, GlaxoSmithKline, Johnson & Johnson |
5925 | Min Hwan Kim | Yonsei University College of Medicine | Analysis of neutrophil to lymphocyte ratio (NLR) in ER+ breast cancer patients to predict palbociclib clinical response | Pfizer |
5930 | Youssef Zeidan | American University of Beirut Medical Center | Evaluation of Radiotherapy Boost in Women with HER-2 positive Breast Cancer | Roche |
5931 | Youssef Zeidan | American University of Beirut Medical Center | Evaluation of Radiotherapy in Triple Negative Breast Cancer: Analysis of the BEATRICE trial | Roche |
5933, 5208 | Ahmad Abuhelwa | University of South Australia | Predictors of exposure, therapeutic and adverse effects of certolizumab pegol and baricitinib used in the treatment of rheumatoid arthritis | Lilly, Roche, UCB |
5940 | Aziz Mezlini | Massachusetts General Hospital | A novel statistical approach to detect the efficacy of drugs that have heterogeneous treatment effects | AbbVie, Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, Lundbeck, Roche, Takeda, UCB |
5944 | Pietro Spitali | Leiden University Medical Center | Prediction of disease progression in Duchenne muscular dystrophy | CureDuchenne |
5945 | Neeraj Narula | McMaster University | Predictors of Mucosal Healing in Ulcerative Colitis: A Post-hoc Analysis of VARSITY | Takeda |
5948 | Georgia Salanti | University of Bern | Making real world predictions for clinical outcomes in Relapsing-Remitting Multiple Sclerosis | Biogen |
5950 | Shirley Wang | Brigham and Women's Hospital | Understanding effectiveness of new drugs in older adults shortly after market entry | Boehringer Ingelheim |
5951, 4543 | Mathilde Nijkeuter | UMC Utrecht | Individualized prediction of recurrence risk reduction and risk of bleeding with extended anticoagulation in patients with venous thromboembolism | Boehringer Ingelheim, Daiichi Sankyo |
5959 | John Dennis | University of Exeter Medical School | Stratification of SGLT2 inhibitor glucose lowering therapy in Type 2 diabetes | Boehringer Ingelheim, Takeda |
5960 | Matt Linnik | Hannover Medical School | Covid-19 Pulmonary Gene Expression Analysis | Lilly |
5963 | Elyse Katz | USSAMMDA | A secondary Data-Analysis to determine treatment effectiveness in Post-Traumatic Stress Disorder | Lilly |
5968 | Mehul Patel | King's College Hospital NHS Foundation Trust | Methods for Staging disease activity In ulcerative colitis; A comparison of endoscopy and Histology (MESIAH) | Johnson & Johnson, Takeda |
5974 | Robert Schoevers | University of Groningen | Prescriber effects on outcome of psychopharmacological treatment of Major Depressive Disorder (MDD) | Lilly |
5981 | Mark Peterson | Vertex Pharmaceuticals | Identifying and quantifying predictors of disease progression in common measures of physical function among boys with Duchenne Muscular Dystrophy (DMD) | CureDuchenne, Lilly |
5982 | Matthew Baker | Stanford University | Investigating the effects of rituximab on specific cell subsets and cytokine levels in systemic lupus erythematosus patients and constructing a prediction model of treatment response | Roche |
5984 | David Baker | Queen Mary University of London | Exploring possibilities to improve the riskbenefit balance through anlaysis of the ocrelizumab phase II extension study | Roche |
5985, 5327 | Jose Antonio Pereira da Silva | Universidade de Coimbra, Portugal | Long-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis: individual patient data meta-analysis | AbbVie, Pfizer, Roche, UCB |
5987, 8728 | Glen Hazlewood | University of Calgary | Disease‐modifying anti‐rheumatic drugs for rheumatoid arthritis: A network meta-analysis incorporating individual patient data | AbbVie, Johnson & Johnson, Lilly, Pfizer, Roche, Sanofi, UCB |
5988 | Elad Sharon | National Cancer Institute | The Role of Targeted Agents and Their Effects on Lymphocytes and Patient Outcomes | Roche |
5989 | Alexandre Betourne | Critical Path Institute | Sharing of Progressive Supranuclear Palsy (PSP) data with the Rare Disease Cures Accelerator - Data and Analytics Platform for Analysis of Outcome Measures and Other Purposes | AbbVie |
5990 | Yan Luo | Kyoto University | Predicting the Treatment Response of Biologics for Individual Patients with Rheumatoid Arthritis: An Individual Participant Data Meta-Analysis | AbbVie, Roche |
6003 | Andrea Quattrone | Magna Graecia University of Catanzaro | Evaluation of disease progression rate in progressive supranuclear palsy using MRI biomarkers: new implications for clinical trials | AbbVie |
6004 | Lily Lim | University of Manitoba | Identifying Trajectories of Disease Activity States in Juvenile Idiopathic Arthritis (JIA) Early After Treatment: Shortening Time to Decision to Change Treatment | Roche |
6006 | Nicholas White | Mahidol University | A Multiple-Dose Study to Assess the Effects of Azithromycin plus Chloroquine on Electrocardiograms in Healthy Subjects - COVID-19 | Pfizer |
6007 | Judith Goldstein | Johns Hopkins School of Medicine | National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) Calibrations for Low Vision Patients with age-related macular degeneration (AMD) | Roche |
6008 | David Hsieh | University of Texas Southwestern Medical Center | Patterns of outcomes and the relevance surrogate endpoints in patients treated with immune checkpoint inhibitors. | Roche |
6041 | Neeraj Narula | Hamilton Health Sciences | Histologic Predictors of Endoscopic Healing in Crohn's Disease | AbbVie |
6050 | Paul Cinciripini | UT MD Anderson Cancer Center | Safety and efficacy of smoking cessation treatments in smokers with and without depression | Pfizer |
6062 | Alex Meisel | University Hospital of Zurich | Neutrophils, Neutrophil-to-Lymphocyte Ratio (NLR) and Neutropenia as Predictors of Treatment Efficacy of Atezolizumab Monotherapy and Atezolizumab-Chemotherapy-Combinations | Roche |
6063 | Wiesje van der Flier | Amsterdam UMC, VUmc | Optimizing Trial design to Achieve Personalized prevention of Alzheimer’s disease | Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, Lilly |
6064 | Neeraj Narula | Hamilton Health Sciences | Comparative Effectiveness of Vedolizumab vs. Infliximab in Ulcerative Colitis | Johnson & Johnson, Takeda |
6066 | Vivek Sharma | University of Louisville | EVALUATING THE ASSOCIATION BETWEEN PROTEINURIA AND THROMBOSIS AND ITS PREDICTORS IN PATIENTS TREATED WITH BEVACIZUMAB | Boehringer Ingelheim, Lilly, Roche |
6068 | Youssef Zeidan | American University of Beirut Medical Center | Evaluation of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Treated with Radiation Therapy and Trastuzumaby | Roche |
6104 | Pratik Sinha | Washington University | Heterogeneous treatment effects in molecular phenotypes of sepsis | Lilly |
6115 | David McAllister | University of Glasgow | Real-world treatment effectiveness of novel anti-diabetic agents in people with type 2 diabetes: Maximising the applicability of clinical trials | AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Lilly, Takeda |
6464 | Michael Wiese | University of South Australia | Individualisation of gout flare prophylaxis when initiating urate-lowering therapy | Takeda |
6471 | Floris Bosch | University of Amsterdam Academic Medical Center | Risk of recurrent venous thromboembolism and bleeding in cancer patients an individual patient data meta-analysis | Pfizer |
6472 | Soong June Bae | Yonsei University Health System | Impact of neutrophil to lymphocyte ratio on prognosis in patients with HER2-positive breast cancer regarding the HER2-targeted therapy | Roche |
6475 | Tobias Polak | Erasmus Medical Center | Combining data from expanded access programs and conventional clinical trials: a statistical application to vemurafenib | Roche |
6477 | Tobias Polak | Erasmus Medical Center | Tositumomab: statistical modeling of expanded access programs and conventional trials | GlaxoSmithKline |
6482 | Andreas Monsch | University of Basel | Analyses of available cognitive data from 200 healthy, German-speaking individuals to be used to examine potential patients
| Takeda |
6483 | Bharati Kumar | University of Bath | Evaluation of available statistical methods performance under non-proportional hazards | AstraZeneca, Lilly |
6484 | Ari Rosenberg | University of Chicago | Developing predictive and prognostic Artificial Intelligent (AI) digital biomarkers for soft tissue sarcoma | Lilly |
6489 | Line Uhrenholt | Aalborg University Hospital | Tapering strategies of biological and targeted synthetic disease-modifying antirheumatic drugs for patients with inflammatory arthritis: a systematic review of randomised controlled trials | AbbVie |
6494 | Maria Alice Franzoi | Jules Bordet Institute | Implications of body mass index on the biological and clinical effects of endocrine therapy and abemaciclib in the neoadjuvant setting | Lilly |
6495, 5485 | Günter Höglinger | Hanover Medical School | Application of improved statistical methodologies for clinical trials in Progressive Supranuclear Palsy | AbbVie |
6496 | Neeraj Narula | Hamilton Health Sciences | Endoscopic Disease Severity and Patient Reported Outcomes in Crohns Disease | AbbVie, Johnson & Johnson |
6498 | Timo Uphaus | University Medical Center Mainz | Identifying patients with unknown stroke etiology who may benefit from a blood thining medication with Dabigatran by a clinically based scoring system | Boehringer Ingelheim |
6499, 5323, 5289 | Ashley Hopkins | Flinders University | Predictors of therapeutic and adverse effects of medicines used in the treatment of breast cancer | AstraZeneca, Boehringer Ingelheim, Lilly, Pfizer, Roche |
6515 | Leire Leache | Navarre Health Service | Cochrane Systematic Review Pharmacotherapy for hypertension induced left ventricular hypertrophy | Boehringer Ingelheim |
6520 | Thomas Schnitzer | Northwestern University | Development of model to predict pain response in clinical trials of chronic pain conditions | Pfizer |
6521 | Ethan Alt | University of North Carolina at Chapel Hill | Bayesian probability of success for multivariate generalized linear models | Biogen |
6532 | Odelia Cooper | Cedars-Sinai Medical Center | A study of how growth hormone treatment affects health outcomes in patients with noncancerous craniopharyngioma tumors | Lilly |
6534 | Diego Tosi | Institut du Cancer de Montpellier | Analysis of breast cancer molecular adaptation to drugs in order to predict relapse after curative treatment | Lilly |
6541 | Dipak Kotecha | University of Birmingham | Big data and meta-analytic approaches for better phenotyping in atrial fibrillation and heart failure | Boehringer Ingelheim |
6543 | Andreas Meid | Heidelberg University Hospital | Reproducible Machine Learning (ML) for Tumor Growth Inhibition (TGI) - can ML methods support the validity of conventional TGI metrics? | Roche |
6544 | Angela Wu | University of Oxford | Investigating the association between smoking cessation and mental health in people with and without psychiatric disorders | Pfizer |
6550 | James Brorson | The University of Chicago | Examination of survivor functions from SOCRATES and THALES trials for kinetics of stroke recurrence | AstraZeneca |
6551 | Siddharth Singh | University of California San Diego | Predicting the short- and long-term risk of serious infections in patients with Crohn’s disease: Analysis of the PYRAMID Registry | AbbVie |
6593 | Matthieu Roustit | Grenoble Alpes University Hospital | Exploration of regional heterogeneity in trials assessing the efficacy of recent non-insulin glucose lowering drugs on cardiovascular outcomes | AstraZeneca |
6594 | Manju Subramanian | Boston Medical Center | The Impact of Race on Short Term Treatment Response to Intravitreal anti-Vascular Endothelial Growth Factor in Diabetic Macular Edema: A Pooled Analysis | Roche |
6601 | Dan Turner | Shaare Zedek Medical Center | Adaptation and validation of the Mucosal Inflammation Non-invasive (MINI) Index for Crohn's disease in adults using the SERENE clinical trial data | AbbVie |
6632 | Luca Valerio | University Medical Center of the Johannes Gutenberg-University Mainz | Healthcare resource utilization and economic burden related to pulmonary embolism. An analysis of the PREFER in venous thromboembolism (VTE) study | Daiichi Sankyo |
6633 | Luca Valerio | University Medical Center Mainz | Performance status and long-term clinical outcomes in pulmonary embolism patients with cancer. An analysis of Hokusai VTE Cancer study | Daiichi Sankyo |
6641 | Anna Feeney | Massachusetts General Hospital | Antidepressants in children and adolescents with Major Depressive Disorder and the influence of placebo response: a meta-analysis | Pfizer |
6642 | Neeraj Narula | Hamilton Health Sciences | Modified Multiplier SES-CD (MM-SES-CD) on Predicting Endoscopic Remission in Crohns Disease | AbbVie, Johnson & Johnson, Takeda |
6686 | Neeraj Narula | Hamilton Health Sciences | Extended Validation of an Ulcerative Colitis Vedolizumab Decision Support Tool | Takeda |
6710 | Gus Slotman | Inspira Health Network | Identifying Patients in the PROWESS SHOCK Clinical Trial Among Whom Drotrecogin Alfa (DrottAA) Reduced Mortality | Lilly |
6712 | Yeon-Mok Oh | Asan Medical Center | Development and validation of a prediction model for the indication of inhaled corticosteroid (ICS) in patients with chronic obstructive pulmonary disease (COPD) | GlaxoSmithKline |
6716 | Nigam Shah | Stanford University | Applying machine learning tools to personalize dabigatran treatment decisions | Boehringer Ingelheim |
6732 | Yung-Chuan Huang | Fu Jen Catholic University Hospital | Decision Tree Model for Dose Selection of Dabigatran in Non-valvular Atrial Fibrillation Patients | Boehringer Ingelheim |
6734 | Andreas Suhrbier | QIMR Berghofer Medical Research institute | The K18 mouse model recapitulates the transcriptomic response to acute COVID-19 Acute Respiratory Distress syndrome (ARDS) in humans | Hannover Medical School |
6739 | Rifaquat Rahman | Dana Farber Cancer Institute | Evaluation of Differences in Trial and Non-Trial Patients and Leveraging of External Data for More Efficient Clinical Trial Designs in Newly Diagnosed Glioblastoma | Project Data Sphere, Roche |
6740 | Georgios Paliouras | National Centre for Scientific Research 'Demokritos' (NCSR-D) | in-silico DMD: Developing computational predictive models for the progression of Duchenne Muscular Dystrophy | CureDuchenne |
6758 | Qian Chen | Hubei Cancer Hospital | Retrospective analysis of the effect of first-line bevacizumab treatment on survival and prognosis of patients with advanced non-small cell lung cancer treated with second-line immunotherapy | Roche |
6759, 5936 | Zhi Xiao | Xiangya Hospital, Central-South University | Roles of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy | Roche |
6762, 5935 | Jian-Guo Zhou
| The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | Bristol Myers Squibb, Project Data Sphere, Roche |
6764 | Johnathan Bartlett | London School of Hygiene & Tropical Medicine | Hypothetical estimand in clinical trials: an application of causal inference and missing data methods | AstraZeneca |
6765 | Dan Hanley | Johns Hopkins University | Pandemic response COVID-19 Research Collaboration Platform | NYU Grossman School of Medicine, Intermountain Healthcare, Washington University School of Medicine, Bassett Research Institute, The Queen's Medical Center, Duke University, University Medical Center New Orleans |
6836 | Alana Rojewski | Medical University of South Carolina | Smoking Cessation Pharmacotherapy Efficacy in Comorbid Medical Populations: Secondary Analysis of the EAGLES Randomized Clinical Trial | Pfizer |
6860 | Nicholas Lange | Columbia University | Belatacept in obese kidney transplant recipients | Bristol Myers Squibb |
6866 | Andy Lim | Monash University | Meta-analysis of early stroke recurrence rate in minor stroke | AstraZeneca |
6869 | Zhen Lin | Robot Bacon Corporation | Evaluating Clinical Trial Data Conventions for the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) | AstraZeneca, Ferox Therapeutics, GlaxoSmithKline, Roche, Takeda |
6881, 5484 | Stefan Leucht | Technical University of Munich | Individual-patient-data (IPD) meta-analysis of the efficacy of clozapine versus second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia | Lilly, Pfizer |
7062 | Julien Edeline | Centre Eugene Marquis | PATIENT REPORTED OUTCOME (PRO) AS A PROGNOSTIC MARKER IN PATIENTS TREATED WITH TARGETED THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA (PRO²-HCC) | Bristol Myers Squibb |
7070 | Georgios Tsakonas | Karolinska Institutet | Anaplastic Lymphoma Kinase- Brain Prognostic Index (ALK-BPI) a novel prognostic score for brain metastasized ALK+ Non Small Cell Lung Cancer (NSCLC) | Roche |
7072 | James Signorovitch | Analysis Group | Development of natural history controls to contextualize clinical trial outcomes of boys with Duchenne muscular dystrophy treated with DS-5141B | CureDuchenne |
7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Boehringer Ingelheim |
7076 | Elias Eriksson | University of Gothenburg | Post hoc patient-level analysis of the impact of amitriptyline, selective serotonin reuptake inhibitors, and placebo of individual items of the Hamilton Depression Rating Scale | GlaxoSmithKline |
7077 | Neeraj Narula | Hamilton Health Sciences | Dominant Patient Reported Outcomes on Predicting Mucosal Healing in Crohns Disease | AbbVie, Johnson & Johnson |
7078 | Alberto Martini
| University of Cincinnati | Role of body mass index and Beta Blockers in metastatic urothelial carcinoma | Roche |
7101 | Jason Luke | University of Pittsburgh | Analysis of gene expression profiles in melanoma tumors exhibiting differential lactate dehydrogenase biomarker levels and correlation with immunotherapy response | Bristol Myers Squibb |
7104 | Jakob Näslund | University of Gothenburg | Item-level effects of adjuvant olanzapine and/or olanzapine monotherapy in treatment-resistant depression | Lilly |
7126 | Alessio Cortellini | Imperial College London | The predictive role of inflammation indices in patients treated with immunotherapy or chemotherapy for advanced non-small cell lung cancer. | Roche |
7127 | Alexa Kimball | Beth Israel Deaconess Medical Center | Effects of adalimumab on inflammation-associated abnormal hematologic patterns in patients with Hidradenitis Suppurativa | AbbVie |
7136 | Shou-Ching TANG | University of Mississippi Medical Center (UMMC) Cancer Center and Research Inst. | Validation of trastuzumab-emtansine (T-DM1) Toxicity Score to predict response to T-DM1 treatment in metastatic breast cancer | Roche |
7140 | Michael J. Sorich | Flinders University of South Australia | Early markers of clinical outcome to ipilimumab therapy for advanced melanoma | Bristol Myers Squibb |
7142 | Sara Tedeschi | Brigham and Women’s Hospital | Causal inference cohort re-analysis of the 'CARES' trial to better understand the roles of colchicine, allopurinol, and febuxostat on cardiovascular events among patients with gout | Takeda |
7143 | Chaim Singal | experiMind | The effects of systemic anti-infective concomitant medications on progression of neurological diseases | Boehringer Ingelheim, GlaxoSmithKline, Lilly, UCB |
7144 | Timothy Perk | AIQ Solutions | External validation of the AIQ predictive score of clinical benefit using Sodium Fluoride (NaF) position emission tomography/computed tomography (PET/CT) images in metastatic prostate cancer (mPC) | Pfizer |
7145 | Joan Busner | Signant Health | Psychometric evaluation of Positive and Negative Syndrome Scale (PANSS) in adolescent schizophrenia trials | Otsuka |
7147 | Carmela Tartaglia | University of Toronto | Exploring the heterogeneity of cognitive profile in patients with Progressive Supranuclear Palsy (PSP) enrolled in the ABBV-8E12 trial and the relationship to brain volumes | AbbVie |
7156 | Angelina Tjokrowidjaja | University of Sydney | Concordance between disease progression by Cancer Antigen 125 and computerized tomography (CT) progression in patients with relapsed advanced ovarian cancer treated with poly(adenosine diphosphate [ADP]–ribose) polymerase inhibitor: a pooled analysis | AstraZeneca |
7158 | Neeraj Narula | Hamilton Health Sciences | Patient Reported Symptoms as Predictors of Endoscopic Improvement in Ulcerative Colitis | Takeda |
7159, 6634 | James Signorovitch | Analysis Group, Inc. | Associations between steroid treatment, functional outcomes and disease milestones among non-ambulatory patients with Duchenne muscular dystrophy (DMD) | CureDuchenne |
7161 | Wesley Kerr | University of California, Los Angeles | Real time monitoring of individual response to antiseizure medication treatment during clinical trials | GlaxoSmithKline, Johnson & Johnson, UCB |
7162 | Andrew Bottomley | European Organisation for Research and Treatment of Cancer (EORTC) | Cancer Clinical Trials Pooling of Quality Life Data (CATAPULT) initiative | Bristol Myers Squibb |
7163 | Laura Mezquita | Hospital Clinic and the Translational Genomics Group at IDIBAPS | Prospective validation of the Lung Immune Prognostic Index in patients with non-small cell and small cell lung cancers | Project Data Sphere, Roche |
7164 | Jörg Ellinger | University Hospital Bonn | Evaluation of CRP (c-reactive protein) flare phenomena as an early predictor of response to the Atezolizumab + Bevacizumab therapy in renal cell carcinoma | Roche |
7224 | Keiichi Fujiwara | Gynecologic Oncology Trial and Investigation Consortium (GOTIC) | Early prediction of survival outcome of large-scale randomized clinical trials using artificial intelligence technology | Boehringer Ingelheim, Lilly, Roche |
7225 | Neeraj Narula | Hamilton Health Sciences | Early vs. Delayed Response to Vedolizumab in Ulcerative Colitis | Takeda |
7227 | Catrin Tudur-Smith | University of Liverpool | Add-on treatment for refractory focal-onset epilepsy: Individual Participant Data Network Meta-analysis | GlaxoSmithKline, Johnson & Johnson, UCB |
7232 | Neil Oxtoby | University College London | Identification of heterogeneity in Alzheimer’s disease clinical trials using computational modelling | Takeda |
7241 | Frederick Reimherr | Psychiatric and Behavioral Solutions, LLC | Retrospective Analysis of Emotional Symptoms in Adults with ADHD and Improvement Produced by Brexpiprazole | Otsuka |
7243 | Emanual Maverakis | University of California Davis | Developing Models from Existing Atopic Dermatitis Outcome Data | GlaxoSmithKline |
7245 | Manabu Takaki | Okayama University | Clinical moderators of response to nalmefene in alcohol dependence: Results from a randomized controlled trial in Japan. | Otsuka |
7274 | Jun Chen | West China Hospital, Sichuan University | Efficacy comparison of biologics (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) in treatment of severe eosinophilic asthma — a network meta-analysis | GlaxoSmithKline |
7277 | David Carter | MMS Holdings | International COVID-19 Data Alliance COVID-19 Workbench | Roche |
7283 | Franziska Michor | Dana Farber Cancer Institute | Large-scale public data reuse to model immunotherapy response and resistance | Bristol Myers Squibb |
7288 | Vipual Jairath | Alimentiv Inc. | Placebo Rates in Inflammatory Bowel Disease: An Individual Patient Data Meta-analysis of Randomized Controlled Trials | AbbVie, Johnson & Johnson, Takeda |
7289 | Gianluca Rigatelli | Rovigo General Hospital | Outcomes of Left Main Purcutaneous Coronary Intervention across age classes | Duke University |
7312 | Marianna Kruithof-de Julio | University of Bern | Machine learning for personalized drug response prediction for bladder and prostate cancer patients | Tempus AI, Inc. |
7317 | Emanual Maverakis | University of California Davis | Developing Efficacy Assessment Tools from Existing Psoriasis Clinical Trial Outcome Data | Lilly |
7321 | Neeraj Narula | Hamilton Health Sciences | A Comparison of the Rapidity of Clinical Response between Infliximab and Tofacitinib for Ulcerative Colitis | Johnson & Johnson, Pfizer |
7322 | Zhengfei Zhu | Fudan University Shanghai Cancer Center | Clinical value and optimal candidate of cranial radiotherapy in atezolizumab-treated advanced non-small cell lung cancer with baseline brain metastasis | Roche |
7323 | Toshifumi Kishimoto | Nara Medical University | Development of the optimal treatment of Nalmefene in patients with alcohol dependence | Otsuka |
7325 | Andreas Artemiou | Cardiff University | Predicting outcomes (death, improvement, survival) of COVID-19 patients on Standard of Care (SoC) | NYU Grossman School of Medicine, Roche, University Medical Center New Orleans |
7379 | Michele Romoli | Bufalini Hospital | Antithrombotics in patent formane ovale (PFO)-related stroke: a meta-analysis stratified for the risk of paradoxical embolism score (RoPE) | Boehringer Ingelheim |
7381 | Tomoya Hirota | University of California San Francisco | Early Prediction of Treatment Response to Antipsychotics for Irritability and Aggression in Autism Spectrum Disorder | Johnson & Johnson, Otsuka |
7384 | Ulrich Mansmann | Ludwig-Maximilian’s University München | Application of Estimands and Causal Reasoning in the Reanalysis of Endpoint Measures in Advanced/Metastatic Non-Small Cell Lung Cancer Clinical Trials | AstraZeneca, Roche, Takeda |
7387 | Neeraj Narula | Hamilton Health Sciences | Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn’s Disease | AbbVie, Johnson & Johnson, Takeda |
7388 | Byeongzu Ghang | Jeju National University Hospital | Reanalysis of CARES study to investigate the changes of estimated glomerular filtration rate after long-term febuxostat or allopurinol treatment in gout patients | Takeda |
7394, 6117, 5895 | Ashley Hopkins | Flinders University | Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers | Roche |
7395 | Xiaoling Shang | Shandong University | Survival analysis of advanced lung adenocarcinoma harboring epidermal growth factor receptor gene mutation receiving the combination treatment of atezolizumab, Bevacizumab,carboplatin and Paclitaxel | Roche |
7396 | Mary Ann Lukas | GSK | Modeling and Simulation of ambrisentan pharmacokinetics in young children | Duke University School of Medicine |
7399 | Yoichi Naito | National Cancer Center Hospital East | Correlation of doxorubicin dose and survival in patients with soft tissue sarcoma; Data from two studies (a larger phase III study and a smaller phase II study) will be combined and analyzed. | Lilly |
7400 | Aryelly Rodriguez | The University of Edinburgh | What are the re-identification risk scores of publicly available anonymised clinical trial datasets? | GlaxoSmithKline, UCB |
7401 | Scott Garrison | University of Alberta | Randomized Controlled Trial Data Availability and Re-Analysis Project | Pfizer, Roche, University of Washington |
7404 | Reena Khanna | Lawson Health Research Institute | A Study to Assess the Correlation Between Harvey Bradshaw Index and Patient Reported Outcome 2 in Crohn's Disease Patients Enrolled in Large Scale Randomized Controlled Trials | Takeda |
7414 | Nobuyuki Horita | Yokohama City University Hospital | Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Trials Evaluating Atezolizumab Regimens for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma: Independent-Patient-Data Analysis. | Roche |
7427 | Joachim Tan | Monash University | Dose reduction and discontinuation of disease modifying anti-rheumatic drugs (DMARDs) for juvenile idiopathic arthritis | AbbVie, Johnson & Johnson, Roche |
7435 | Noah Goldfarb | University of Minnesota | Decision tool for the use of adalimumab for hidradenitis suppurativa | AbbVie |
7445 | Catherine Thieblemont | Inserm | Evaluation of surrogate markers in marginal zone lymphoma | Roche |
7462 | Junjie Zhuo | Hainan University | Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles with Clinical Profiles in the Progression of Alzheimer’s Disease | AstraZeneca |
7492 | Yang Zhao | Nanjing Medical University | An Investigation on the Role of Blood Biomarkers as Predictors for Individualized Treatment Regimen Selection in Non-Small Cell Lung Cancer. | Roche |
7493 | Nina Hilkens | Radboudumc Nijmegen | Blood pressure variability and progression of white matter hyperintensities after ischemic strokes | Boehringer Ingelheim |
7495 | Thomas Antalffy | Smart Respiratory Products Ltd | Analysing Clinical Applicability of CompEx Endpoints | AstraZeneca |
7498 | Riccardo Polosa | Center of Excellence for the Acceleration of Harm Reduction (CoEHAR) | A Machine Learning approach to improve smoking cessation trials | Pfizer |
7501 | Min-Gul Kim | Jeonbuk National University Hospital | COVID-19 clinical trial data utilization to develop external control datasets in COVID-19 therapeutics development | HCor Research Institute, Hospital Universitario Austral, Lilly, Montreal Heart Institute, Roche, University of Minnesota |
7503, 6635 | Leslie Padrnos | Mayo Clinic | Efficacy and safety of anticoagulants for the treatment of acute venous thromboembolism (VTE) in patients with hematologic malignancies a systematic review and individual patient level data meta-analysis | Boehringer Ingelheim, Daiichi Sankyo, Pfizer |
7518 | Lucio Manenti | University Hospital of Parma | Role of persistent and isolated reduced serum complement 3 (sC3) in lupus nephritis | Roche |
7520 | Malathi Ram | Johns Hopkins University | ACEi/ARB medications for hospitalized patients with COVID-19 – an individual patient data (IPD) based pooled analysis | Bassett Medical Center, Sharp Healthcare, University of Kansas Medical Center, University of Minnesota |
7535 | Joshua Drago | Memorial Sloan Kettering Cancer Center | Statin use and clinical outcomes on ado-trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer | Roche |
7539 | Amit Etkin | Alto Neuroscience, Inc. | Clinical and demographic predictors of antidepressant treatment in patients with major depressive disorder with agomelatine versus vortioxetine | Lundbeck |
7541 | Amit Etkin | Alto Neuroscience, Inc | Role of clinical, historical and demographic factors in the response to antidepressants versus placebo | Lilly, Takeda |
7542 | Neeraj Narula | Hamilton Health Sciences | Vedolizumab vs. Adalimumab in Ulcerative Colitis: Validation of Indirect Comparisons | AbbVie, Takeda |
7543 | Margaret Salisbury | Vanderbilt University Medical Center | Defining the physiologic trajectory of presymptomatic through advanced pulmonary fibrosis | Boehringer Ingelheim, Roche |
7544 | Abhimanyu Mahajan | Rush University Medical Center | Sensory trick and benefit from botulinum toxin in cervical dystonia | AbbVie |
7549 | Vipul Jairath | Alimentiv Inc | Responsiveness of the UC-100 Score in Patients with Moderately to Severely Active Ulcerative Colitis | AbbVie, Johnson & Johnson, Takeda |
7552 | Anna van Eijk | Liverpool School of Tropical Medicine | Impact of Malaria in Pregnancy on Infants | Pfizer |
7581 | Rustam Al-Shahi Salman | University of Edinburgh | Collaboration Of Controlled Randomised trials of Oral Antithrombotic agents after intraCranial Haemorrhage (COCROACH) | Daiichi Sankyo |
7583, 5932 | Youssef Zeidan | American University of Beirut Medical Center | Evaluation of Radiotherapy after Complete Response to Neoadjuvant Chemotherapy in HER-2 Positive Breast Cancer Patients | Roche |
7587 | Yashmin Karten | Critical Path Institute | Development of model-informed drug development tools for Alzheimer's Disease | Lilly |
7590 | Noémie Lang | University Hospitals of Geneva | FRILLY: a retrospective single center study on Fractionated Rituximab to avoid Lysis Syndrome in Aggressive B-Lymphoma | Project Data Sphere, Roche |
7591, 7392 | Neeraj Narula | Hamilton Health Sciences | Predictors of Placebo Response and Remission in Ulcerative Colitis and Crohn’s Disease | AbbVie, Johnson & Johnson, Pfizer, Takeda |
7592 | Alexandre Betourne | Critical Path Institute | Integration of Biogen Rare Disease Data into the Rare Diseases Cures Accelerator Data and Analytics Platform (RDCA-DAP) | Biogen |
7595 | Ashley Hopkins | Flinders University | Predicting therapeutic and adverse outcomes to immune checkpoint inhibitors used in cancer treatment | Roche |
7597 | Junko Takeshita | University of Pennsylvania | Evaluating Racial and Ethnic Differences in the Quality-of-Life Impact of Atopic Dermatitis | Lilly, Pfizer, Regeneron |
7598 | Harry Southworth | Data Clarity Consulting Ltd | Exploration of ailments related to back pain in the medical history data from clinical studies of healthy subjects using formal hypothesis testing and data mining | AstraZeneca, GlaxoSmithKline |
7599 | Hwanhee Hong | Duke University | Combining data sources to identify effect moderation for personalized mental health treatment | Johnson & Johnson, Lundbeck, Takeda |
7601 | Guru Sonpavde | AdventHealth Cancer Institute | Mathematical prognostic model utilizing multi-platform dynamics in patients with metastatic urothelial carcinoma receiving post-platinum PD1/L1 inhibitors | Roche |
7606 | Amber Salter | University of Texas Southwestern Medical Center | Comorbidity and Clinical Trials of Disease-Modifying Therapies in Multiple Sclerosis | Roche |
7609 | Joao Pedro Ferreira | Porto University | The impact of albiglutide on heart failure outcomes among patients with type 2 diabetes with and without heart failure at baseline | GlaxoSmithKline |
7620 | Emilie Sbidian | University Paris Est Creteil (UPEC) | Systemic pharmacological treatments for chronic plaque psoriasis A Systematic Review and an Individual-Patient Data Network Meta-Analysis of Randomized Controlled Trials | AbbVie, Johnson & Johnson, Lilly, Pfizer, UCB |
7621 | Adam Boxer | University of California San Francisco | Bayesian Disease Progression Modeling and Clinical Trial Design for Progressive Supranuclear Palsy - Richardson's Syndrome | AbbVie |
7654 | Shirley Yu | University of Sydney | Update of individual data meta-analysis of intra-articular corticosteroids in knee and hip osteoarthritis | Sanofi |
7656 | Neeraj Narula | Hamilton Health Sciences | Impact of Steroid Weaning Regimens on Outcomes in Clinical Trials of Ulcerative Colitis | AbbVie, Johnson & Johnson, Pfizer, Takeda |
7658 | Arman Sabbaghi | Purdue University | Tripartite Estimands for Adherence Causal Inference in Clinical Trials, With Applications for the Development of COVID-19 Treatments | Sanofi |
7660 | Shirley Yu | University of Sydney | Predictors of placebo response to local (intra-articular) therapy in osteoarthritis: an individual patient data meta-analysis | Sanofi |
7661 | Baocheng Chang | Tianjin Medical University | Effects of Lixisenatide on the primary prevention of diabetic kidney disease in population with high risk | Sanofi |
7662 | Benoit You | Université Claude Bernard Lyon | Prognostic And Predictive Value Of The Modeled PSA Kinetics Parameters In Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel Or Cabazitaxel (Phase III Trial — FIRSTANA) | Sanofi |
7663, 7385 | Amit Etkin | Alto Neuroscience, Inc. | Cognitive predictors of antidepressant treatment outcome in patients with major depressive disorder | Lilly, Lundbeck, Takeda |
7667 | Ashley Hopkins | Flinders University | Summarising the therapeutic and adverse effects of anticancer medicines according to race and sex: pooled analysis of clinical trials of contemporary treatments for solid tumours | AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Johnson & Johnson, Lilly, Pfizer, Roche,
Sanofi, Takeda |
7743 | Caroline Quach | CHU Sainte-Justine | Is there a Difference in the Immune Response, Efficacy, and Safety of Seasonal Influenza Vaccine in Males and Females? - A Meta-Analysis | Sanofi |
7744, 6055 | Florian Naudet | CHU Rennes | Inferential reproducibility of therapeutic research: a registered report for a cross-sectional study of RCTs available on major data-sharing platforms | AbbVie, Boehringer Ingelheim, Lilly, Pfizer, Roche, Sanofi, Takeda, UCB |
7758 | Nahid Sultana | University of Sheffield | Indirect comparisons of time-to-event outcomes using single-arm studies in health technology assessment (Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma) | GlaxoSmithKline |
7759 | Tamar Oostrom | The Ohio State University | Heterogenous Effects in Diabetes Mellitus Clinical Trials and Implications for Physician Prescriptions | GlaxoSmithKline, Sanofi |
7760 | John (Devin) Peipert | Northwestern University | Study of Functional Assessment of Chronic Illness Therapy (FACIT) GP5 Item as a Measure of Treatment Tolerability in Advanced Cancer Patients across Multiple Tumour Sites and Treatment Types | Lilly, Pfizer, Roche |
7772 | Neeraj Narula | Hamilton Health Sciences | Combined Histologic and Endoscopic Endpoints in Ulcerative Colitis | Takeda |
7776 | Stefan Leucht | Technical University of Munich | Antipsychotic drugs versus placebo in the treatment of antipsychotic naïve and/or first episode children or adolescents with psychosis: A systematic review and meta-analysis of double-blind randomized controlled | Lilly, Otsuka |
7777 | Paul Ayuk | Newcastle-upon-Tyne Hospitals NHS Trust | Using Dabigatran etexilate to prevent blood clots in women after childbirth | Boehringer Ingelheim |
7779 | Luís Inês | University of Beira Interior | Derivation and validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) severe disease activity category: post-hoc analysis of the anifrolumab clinical trials in active systemic lupus erythematosus. | AstraZeneca |
7782 | Yang Li | Renmin University of China | A new covariate randomization method for multi-arm randomized controlled trials | GlaxoSmithKline |
7785 | Christian Jonasson | NordicRWE | Using Norwegian real world data to emulate and reproduce results from oncology clinical trials | Roche |
7794 | Joan Carles | Vall D'Hebron Institute of Oncology | Co Medication (aspirin, statins and metformin) analysis in patients with metastatic Castration Resistant Prostate Cancer treated with Chemotherapy | Sanofi |
7797 | Jörg Ellinger | University Hospital Bonn | Evaluation of the performance of the modified Glasgow prognostic score in urothelial carcinoma, non-small cell lung cancer and renal cell carcinoma | Pfizer, Project Data Sphere, Roche |
7801, 6864 | Yoshie Omachi | National Center of Neurology and Psychiatry | Elucidation of the predictive factors for active and placebo drug response on social functioning and quality of life (QOL) in psychiatric illnesses including developmental disorders | Johnson & Johnson, Lilly, Shionogi |
7804 | Qingyun Li | Genecast Biotechnology Co., Ltd | An exploratory study of the fusion co-mutated immune microenvironment in Non-small cell lung cancer | Roche |
7807 | Hayato Niiyama | Yokohama City University | A Post-hoc Analysis using Secondary Data of Clinical Trial from M14-033 Study to Evaluate Average Treatment Effect and Heterogeneous Treatment Effect of Adalimumab in Maintenance Phase for Patients with Ulcerative Colitis | AbbVie |
7809 | David James Pinato | Imperial College, London | The predictive role of concomitant antibiotics in patients treated with immunotherapy or oral treatment for unresectable hepatocellular carcinoma (HCC) | Roche |
7810 | Diego Chowell | Icahn School of Medicine at Mount Sinai | Machine learning model to predict cancer immunotherapy response | Roche |
7811 | Gustavo Turecki | McGill University | Using Artificial Intelligence to Personalize Treatment Selection and Trajectory Monitoring of Bipolar Disorder | AbbVie, Lilly, Otsuka, Takeda |
7817 | Neeraj Narula | Hamilton Health Sciences | Predictors of Histologic Response using Antibodies Against Interleukin-5 in Eosinophilic Esophagitis | GlaxoSmithKline |
7818 | Werner Weitschies | University of Greifswald | Development and improvement of an in vitro tool, which simulates the physiological characteristics of the ascending colon | Sanofi |
7819 | Jeanine Roeters van Lennep | Erasmus University Medical Center | Efficacy & Safety of Proprotein Convertase Subtilisin/Kexin type 9 Inhibitors: a Systematic Review and Meta-analysis of Real-World Data | Sanofi |
7822 | Linbin Lu | the 900th Hospital of PLA | Trajectories of alpha-fetoprotein and liver cancer outcomes after atezolizumab treatment | Roche |
7823 | Marc Carrier | University of Ottawa | Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Patients with Cancer: A Systematic Review | GlaxoSmithKline, Sanofi |
7824 | Feng Sun | Peking University | An individual participant data meta-analysis to evaluate PD1 vs PD-L1 Inhibitors in Asian subgroup Cancer patients | Daiichi Sankyo, Roche |
7828 | Ramiro Sofia | Leiden University Medical Center | SPondyloarthritis EARly Definition (ASAS-SPEAR) Analysis of Symptom Duration Thresholds Using Pooled Data from Randomized Controlled Trials | AbbVie, Johnson & Johnson, Lilly, Pfizer, UCB |
7830 | Yi-Wen Tsai | National Yang Ming Chiao Tung University | Cost effectiveness analysis of atezolizumab plus chemotherapy for untreated extensive stage small cell lung cancer in Asia | Roche |
7835 | Hiroyuki Kusuhara | University of Tokyo | Assessment of the drug-drug interactions risks of drugs based on the clinical data of the plasma biomarkers | AbbVie |
7840 | Marco Tagliamento | IRCCS Ospedale Policlinico San Martino | Clinical Effect of Chemotherapy-Immunotherapy Combination in the First-Line Treatment of Older Patients with Non-Small Cell Lung Cancer | Roche |
7842 | Marco Tagliamento | IRCCS Ospedale Policlinico San Martino | Pooled Efficacy and Safety Analysis of the Phase III Studies of Alectinib vs. Crizotinib in Untreated ALK-Positive Non-Small Cell Lung Cancer | Roche |
7844 | Linong Ji | Peking University People's Hospital | Risk stratification and responder identification for glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) in Type 2 Diabetes Mellitus (T2DM): a machine learning facilitated post-hoc analysis of clinical trials | BioLINCC, GlaxoSmithKline, Johnson & Johnson |
7845 | Craig Nelson | University of California San Francisco | Change in cognition during antidepressant treatment of late life depression | Lilly, Lundbeck |
7848 | Jennifer Lund | University of North Carolina at Chapel Hill | Improving Colon Cancer Therapy Decisions by Extending Trial Representation | Sanofi |
7849 | Igor Stojkov | Paul-Ehrlich-Institut | Determinants of study design for vaccines against opportunistic bacterial infections a proof-of-concept for data-driven, individual patient data (IPD) analyses. | Sanofi |
7850 | Vipul Jairath | University of Western Ontario | Impact of concomitant baseline medication on efficacy of biologics and small molecules for Inflammatory Bowel Disease | AbbVie, Johnson & Johnson, Pfizer, Takeda, UCB |
7854 | Vipul Jairath | University of Western Ontario | Efficacy of medical therapies for ulcerative colitis according to disease distribution: An individual patient data meta-analysis of randomized controlled trials | AbbVie, Johnson & Johnson, Pfizer, Takeda |
7856 | Evandro de Azambuja | Institut Jules Bordet | Metastatic HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab: the impact of early response on patient survival | Roche |
7857 | Rentao Yu | Chongqing Medical University | Cutaneous adverse effects of immunotherapy medications in the treatment of cancers and their associations with overall survival | Daiichi Sankyo, Roche |
7858 | Jie Zha | Xiamen University | Retrospective cohort study with internal and external validation of a predictive tool for progression of disease within 2 years (POD24) risk assessment in follicular lymphoma patients | Roche |
7860 | Kemi Williams | 54gene | Descriptive analysis of UNITY Global study data in Nigeria | Certara |
7868 | Anne-Marie Dingemans | Erasmus MC University Medical Center | Predictive clinical characteristics for weight gain in patients treated with alectinib | Roche |
7872 | Dorra Bouazzi | Zealand University | Hidradenitis Suppurativa – a collaborative study of subtypes | AbbVie |
7873 | Xue Yang | Beijing Cancer Hospital | Crizotinib followed by alectinib vs alectinib alone: analysis of treatment-naïve patients with non-small cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) -rearrangement | Roche |
7874 | Chiara Alessandra Cella | Istituto Europeo di Oncologia | Addressing the synergistic effect of metformin in patients with Pancreatic neuroendocrine tumors treated with sunitinib: a post-hoc analysis from the main pivotal trials. | Pfizer |
7875 | Marco Valgimigli | Cardiocentro Ticino, Lugano and Universita della Svizzera ltaliana (USI) | P2Y12 inhibitor or Aspirin moNoTHERapy as secondary prevention in patients with coronary artery disease: in individual patient data meta-analysis (PANTHER collaborative initiative) | Sanofi |
7882 | José González-Gomariz | Fundacion para la Investigacion Medica Aplicada (FIMA) | Study of the expression of several cytokines related with the survival of advanced melanoma patients | Bristol Myers Squibb |
8052 | Wataru Fukuokaya | The Jikei University School of Medicine | Association of serum magnesium levels with effectiveness of atezolizumab in advanced urothelial carcinoma | Roche |
8053 | Alexander G Mathioudakis | Manchester University NHS Foundation Trust | ICS-RECODE: Predictors of treatment REsponse to inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease: randomised COntrolled trials individual participant Data re-Evaluation. | AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline |
8056 | Ashley Hopkins | Flinders University | Summarising the therapeutic and adverse effects of antibody-drug conjugates in older women with breast cancer: A review of clinical trial individual-participant data | Roche |
8058 | Howard Smith | Sheffield Teaching Hospitals | An individual patient data meta-analysis of clinical endpoints in pulmonary hypertension with interstitial lung disease (PH-ILD) | Boehringer Ingelheim, Johnson & Johnson |
8175 | Guoxing Wan | Hubei University of Medicine | Efficacy and safety of atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade | Roche |
8180 | Sheng Luo | Duke University | Clinical and molecular characteristics of human epidermal growth factor receptor 2-positive and human epidermal growth factor receptor 2-negative breast cancer | Daiichi Sankyo, Lilly, Pfizer, Roche |
8236 | Gao-Jun Teng | Zhongda Hospital, Southeast University | The role of prior transarterial chemoembolization in atezolizumab plus bevacizumab in hepatocellular carcinoma | Roche |
8244 | Frank Doyle | Royal College of Surgeons Ireland | Do psychometrics matter? The effects of advanced psychometric analyses on depression randomised trial outcomes | GlaxoSmithKline, Lilly, Pfizer, Takeda |
8263 | George Ntaios | University of Thesaly | Risk of myocardial infarction in patients with paroxysmal vs. non-paroxysmal atrial fibrillation: an individual patient data meta-analysis of the ENGAGE-AF and RE-LY trials | Boehringer Ingelheim, Daiichi Sankyo |
8266 | Shenghong Zhang | The first affiliated hospital of Sun Yat-sen University | The prognostic value of faecal calprotectin for long-term outcomes in ulcerative colitis | Takeda |
8287 | Damian J. Ralser | University Hospital Bonn | Evaluation of the easy-to-implement modified Glasgow prognostic score (mGPS) in patients with previously treated human epidermal growth factor receptor 2-positive advanced breast cancer in the KATE2 clinical trial | Roche |
8294 | Neeraj Narula | Hamilton Health Sciences | Extended Validation of an Ulcerative Colitis Vedolizumab Decision Support Tool for Outcome Prediction with Tofacitinib | Pfizer |
8315 | Chiara Tani | University of Pisa | Evaluation of gender differences in the efficacy and safety of belimumab in the treatment of active systemic lupus erythematosus | GlaxoSmithKline |
8316 | Vipul Jairath | Alimentiv | Correlation Between Symptoms and Objective Measures of Disease Activity in Patients with Moderate to Severe Ulcerative Colitis and Crohn’s Disease | AbbVie, Johnson & Johnson, Pfizer, Takeda |
8324 | Jeroen Dekervel | Universitaire Ziekenhuizen Leuven | Response Evaluation Criteria in Solid Tumors (RECIST) vs modified RECIST response durability in advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab | Roche |
8325 | Xiaodan Tang | Northwestern University | Does scoring method impact estimation of significant individual changes using Patient-Reported Outcomes Measurement Information System (PROMIS) measures? Comparing Classical Test Theory versus Item Response Theory | AbbVie |
8327 | Eva Hoster | Ludwig-Maximilian University Munich | Constructing estimands for overall survival within causal frame work for dynamic treatment schemes in oncology: Simulation and a clinical trial example | Roche |
8342, 7444 | Gus Slotman | Inspira Health Network | IDENTIFYING TOCILIZUMAB-RESPONSIVE COVID-19 PATIENTS FROM COVACTA, EMPACTA, AND REMDACTA RANDOMIZED CLINICAL TRIAL PRE-RANDOMIZATION DATA | Roche |
8344 | Xiaoling Shang | Shandong University | A clinical variable based-Nomogram could predict survival for Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide | Roche |
8347 | Hong Jae Chon | CHA Bundang Medical Center | Thyroid immune-related adverse events correlated with favorable clinical outcome in patients with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab | Roche |
8349 | Nqoba Tsabedze | University of Witwatersrand | The efficacy of beta-blockers on morbidity and mortality endpoints in black hypertensive patients: A meta-analysis | GlaxoSmithKline |
8377 | Neeraj Narula | Hamilton Health Services | Estimating Differences in the Comparison of Outcomes in Clinical Trials for Ulcerative Colitis Patients using Patient-Level Data and Aggregated Data Network Meta-Analysis | AbbVie, Johnson & Johnson, Pfizer, Takeda |
8427 | Ahmad Abuhelwa | University of Sharjah | Predictors of exposure, therapeutic and adverse effects of medicines used in the treatment of multiple myeloma | Johnson & Johnson, Sanofi, Takeda |
8435 | Hui Zheng | Chengdu University of Traditional Chinese Medicine | Predictors of galcanezumab in the preventive treatment of migraine | Lilly |
8436 | David Schade | NM Non profit Society to Prevent Symptomatic Heart Disease | Development of an Atherosclerosis Reversal Calculator | AstraZeneca |
8438 | Sheng Luo | Duke University | Development of novel statistical methods to detect treatment effect in Alzheimer’s disease clinical trials over time | AbbVie |
8440 | David Seiffge | Insel Gruppe AG | Andexanet alfa and the risk of haematoma expansion in patients with non-traumatic intracerebral haemorrhage – a pooled individual patient data analysis of ANNEXA-4 ICH and TICH-NOAC | AstraZeneca |
8442 | Yi Lisa Hwa | Mayo Clinic | Better outcomes among multiple myeloma patients who are taking beta-blockers while receiving chemotherapy. | Sanofi |
8443 | Lane Desborough | Nudge BG, Inc. | Aerobic and Anaerobic Exercise Effects on Blood Glucose and Insulin | Jaeb Center for Health Research Foundation, Inc. |
8445 | Kelley Kidwell | University of Michigan | Use of external control with longitudinal data for drug evaluation in Duchenne muscular dystrophy a Bayesian small sample, sequential, multiple assignment randomized trial design (snSMART) | CureDuchenne, Lilly |
8446, 7479, 7075 | Elias Eriksson | University of Gothenburg | Efficacy of serotonin reuptake inhibitors in children and adolescents | AbbVie, GlaxoSmithKline, Lilly, Lundbeck, Pfizer |
8450 | Dennis McGonagle | University of Leeds | The effect of Body Mass Index (BMI) and Age on Baricitinib efficacy in Covid-19 patients | Lilly |
8542 | João Sérgio Neves | Faculty of Medicine of University of Porto | Albiglutide and Cardiovascular Outcomes in Type 2 Diabetes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use | GlaxoSmithKline |
8546 | Alice Adenis | Diabeloop SA | Modeling the impact of physical activity, estimated by sensors such as accelerometers and heart rate, on glycemia of Type 1 Diabetes (T1D) patients | Jaeb Center for Health Research Foundation, Inc. |
8555 | Gijsbert Stoet | University of Essex | Effects of exercise on blood glucose levels, food intake and insulin use in adult T1D patients | Jaeb Center for Health Research Foundation, Inc. |
8557 | Fan Ge | Guangzhou Medical University | Organ-specific metastatic landscape dissects programmed death ligand-1 (PD-L1) blockade efficacy in advanced cancer | Lilly, Roche |
8558 | Pablo Guisado Vasco | Hospital Universitario Quironsalud Madrid | Investigating the impact of antibodies against SARS-CoV-2 on the effectiveness of interleukin-6 inhibitors in Covid-19 patients | Roche |
8559 | Dag Aarsland | King’s College London | Predicting Cognitive Abilities and Treatment Outcome of Major Depressive Disorder in Elderly Patients Using Vortioxetine and Duloxetine Antidepressants | Lundbeck |
8561 | Dale Morrison | The University of Melbourne | IMPROVING EXERCISE WITH TYPE 1 DIABETES | Jaeb Center for Health Research Foundation, Inc. |
8562 | Raquibul Hannan | UT Southwestern Medical Center | Long-term outcomes of renal cell carcinoma patients with stable and progressive disease following treatment with Ipilimumab and Nivolumab in randomized controlled trial | Bristol Myers Squibb |
8563, 9228 | Kenta Yoshida | Genentech, Inc. | Tumor Growth Inhibition-Overall Survival (TGI-OS) model development and validation for hormone receptor positive (HR+)human epidermal growth factor receptor 2 negative (HER2-) breast cancer | AstraZeneca, Pfizer |
8564 | SANGWOO KIM | Yonsei University Health System | Development of Immune Phenotype-specific Immune Checkpoint Inhibitor Response (anti-programmed death ligand-1) Prediction Algorithm | Bristol Myers Squibb |
8569 | Gus Slotman | Inspira Health Network | USING PRE-RANDOMIZATION DATA TO IDENTIFY PATIENTS WITH COVID-19 AMONG WHOM FLUVOXAMINE OR IVERMECTIN IMPROVED OUTCOMES | Platform Life Sciences |
8576 | Dafne Capelusnik | Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands | Validating a Personalised Ankylosing Spondylitis Metrology Index | AbbVie, Johnson & Johnson, Lilly, Pfizer, UCB |
8577 | Yao Zhu | Fudan University Shanghai Cancer Center | The impact of long-term proton pump inhibitors use on the prognosis of patients receiving Androgen-annihilation therapy | Bayer |
8581 | Masahiro Takeuchi | The University of Tokyo | Repositioning of neurological drug Aripiprazole for Amyotrophic lateral sclerosis (ALS) patients | Otsuka |
8582 | David Cherne | University Health Network | Modelling Studies to Assess Sodium-Glucose co-Transporter-2 (SGLT2) Inhibition Effects and Kidney Protection in Type 1 Diabetes | AstraZeneca, Boehringer Ingelheim |
8585 | Daniel Schachter | Unigranrio | Efficacy of Calcitonin gene-related peptide (CGRP) monoclonal antibodies for medication overuse headache in chronic migraine patients A systematic review and meta-analysis | Lilly, Lundbeck |
8588 | Wenlong Zhong | Sun Yat-sen Memorial Hospital of Sun Yat-sen University (SYSU) | The influence of antibiotics on survival outcomes for bladder cancer patients being treated with immune checkpoint inhibitor therapy | Roche |
8591 | John Reynolds | University of Birmingham | Patterns of skin flare in patients with systemic lupus erythematosus | AstraZeneca |
8593 | Hyon Choi | Massachusetts General Hospital | Serum urate reduction, gout flares, and risk of major cardiovascular events during urate-lowering therapy initiation target trial emulation and self-controlled case series analysis | Takeda |
8602 | Robert Hamilton | University of Toronto | Statin use and prostate cancer outcomes in patients treated in the ARAMIS trial | Bayer |
8603 | Wencai Jiang | Chengdu Second People's Hospital | Predictive value of high‐sensitivity cardiac troponin‐T for Major Adverse Cardiovascular Events in patients with Chronic coronary heart disease | GlaxoSmithKline |
8606 | Daria Igudesman | AdventHealth Translational Research Institute | Evaluating the association of eating window duration and timing of calorie distribution with glycemic parameters and body weight | Jaeb Center for Health Research Foundation, Inc. |
8609 | Fredrik Schjesvold | Oslo University Hospital | Personalized prediction of progression-free survival in multiple myeloma patients treated with isatuximab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone only, using combined machine learning and mechanistic modeling. | Sanofi |
8611 | Adam de Havenon | Yale University | Baseline Stroke Severity in Secondary Prevention Trials | Boehringer Ingelheim |
8615 | Monia Rekik | Université Laval | Using artificial intelligence to predict and prevent physical activity induced hypoglycemia and hyperglycemia in type 1 diabetes | Jaeb Center for Health Research Foundation, Inc. |
8656 | Meg Jardine | The University of Sydney | The RAAS inhibition in COVID-19 Trialists Collaboration (RiCTC) | University of Minnesota, Bassett Medical Center |
8684 | José da Silva | Centro Hospitalar e Universitário de Coimbra | Comparing the prevalence of Boolean-based remission based on 3 versus 4 variables and their association with radiographic outcomes in rheumatoid arthritis using data from Tofacitinib studies | Pfizer |
8686 | Andrea E. van der Meulen - de Jong | Leiden University Medical Center | Anemia and therapy with Janus Kinase Inhibitors in patients with ulcerative colitis | Pfizer |
8688 | Grace Lu-Yao | Thomas Jefferson University | Anemia and therapy with Janus Kinase Inhibitors in patients with ulcerative colitis | GlaxoSmithKline, Johnson & Johnson, Sanofi |
8699 | Niklas Klümper | University Hospital Bonn | Evaluation of baseline and on-treatment serum biomarkers to predict immunotherapy response in solid cancers | Roche |
8700 | Leo Buckley | Brigham and Women's Hospital | Colchicine Adverse Effects Research in people with Covid-19 randomized to colchicine treatment | Montreal Heart Institute |
8712 | Amit Manjrekar | Medtronic Diabetes | T1-DEXI Analysis for Exercise Study | Jaeb Center for Health Research Foundation, Inc. |
8716 | Ali Cinar | Illinois Institute of Technology | Data Analysis, Classification and Model Development using Continuous Glucose Monitoring (CGM) and Physical Activity Data of people with Type 1 Diabetes | Jaeb Center for Health Research Foundation, Inc. |
8720 | George Ntaios | University of Thessaly | Association between statin treatment and cardiovascular outcomes in patients with atrial fibrillation | Boehringer Ingelheim, Daiichi Sankyo |
8721 | Jorge Bondia | Universitat Politècnica de València | Modeling of exercise and meal disturbances under free-living conditions for improved performance of single- and dual-hormone artificial pancreas systems | Jaeb Center for Health Research Foundation, Inc. |
8722 | Daniele Robesti | Ospedale San Raffaele | Assessing the Androgen indifferent prostate cancer patients reponse to novel antiandrogen-based regimen or taxanes. | Johnson & Johnson, Sanofi |
8724 | Joel Skaistis | Corewell Health | Effect of Tafamidis on Dementia Medication Initiation: A Post-Hoc Analysis of the ATTR-ACT Trial | Pfizer |
8729 | Octavian Adam | Albany Medical College | Time to Initiation of Symptomatic Treatment in untreated Parkinson Disease | Biogen |
8750 | Manit Srisurapanont | Chiang Mai University Faculty of Medicine | Depressive Symptoms Responding to Bupropion A Differential Item Functioning Approach in Patients with Major Depressive Disorder | GlaxoSmithKline |
8751 | Diederik Dippel | Erasmus MC University Medical Center | Prediction of the treatment benefit of intravenous alteplase treatment for acute ischemic stroke | Boehringer Ingelheim |
8752 | Michelle Condren | University of Oklahoma | Type 1 Diabetes and Exercise-Helmsley Trust RFP | Jaeb Center for Health Research Foundation, Inc. |
8753 | Yu-Han Chiu | Harvard T.H. Chan School of Public Health | Dabigatran versus Warfarin in Patients with Atrial Fibrillation Extending inference from the RE-LY trial to real world target population | Boehringer Ingelheim |
8756 | Eyal Dassau | Eli Lilly and Company | Assessment of insulin utilization and insulin delivery metrics in people with type 1 diabetes mellitus using blood glucose excursions, combined with nutrition and exercise information from the T1-DEXI dataset | Jaeb Center for Health Research Foundation, Inc. |
8757 | Sandra Tessa Hattenhauer | University Hospital Bonn | Baseline immune signature score as predictor for response to atezolizumabbevacizumab in hepatocellular carcinoma | Roche |
8758 | Michael Szarek | CPC Clinical Research | Comparison of RGX-202-01 with ramucirumab or aflibercept in the treatment of patients with recurrent colorectal cancer harboring a RAS mutation | Lilly, Sanofi |
8760, 4112 | Florian Naudet | CHU de Rennes | Tolerability of duloxetine in the elderly and in younger adults: a systematic review and individual patient data meta-analysis of randomized controlled trials versus placebo. | AbbVie, Lilly, Lundbeck, Pfizer, Takeda |
8764 | Giuseppe Cabibbo | University of Palermo | Competing risk factors in survival analyses for advanced hepatocellular carcinoma outcomes. The key role of liver function and impact of drug class | Roche |
8765 | Amit Etkin | Alto Neuroscience | Understanding individual differences in response to roflumilast in schizophrenia | AstraZeneca |
8766 | Catherine Russon | University of Exeter | Using machine learning methods to predict the risk of exercise-induced hypoglycemia in people with Type 1 diabetes | Jaeb Center for Health Research Foundation, Inc. |
8767 | Armando Turchetta | McGill University | Forecasting recruitments in multicenter clinical trials via the time-dependent Poisson-Gamma model | Roche |
8768 | Ryan Mizell | Advent Health | Predicting progression in Primary Progressive Multiple Sclerosis with Machine Learning | Roche |
8769 | Hyung Seok Park | Yonsei University Health System | A novel prediction model of poly ADP ribose polymerase (PARP) inhibitor sensitivity using genomic analyses | Pfizer, Inc. |
8773, 6118 | Roxana Mehran | Icahn School of Medicine at Mount Sinai | Antithrombotic therapy in patients with atrial fibrillation after percutaneous coronary intervention: a systematic review and individual patient data network meta-analysis. | Boehringer Ingelheim, Daiichi Sankyo |
8774 | Paco Welsing | University Medical Center Utrecht | Using the “potential-outcomes framework” to predict added value of more intensive initial therapy for individual early Rheumatoid Arthritis (RA) patients | Roche |
8775 | Shenghong Zhang | The first affiliated hospital of Sun Yat-sen University | Predictors for therapeutic outcomes in patients of ulcerative colitis receiving Janus kinase inhibitors | Galapagos, Pfizer |
8802 | Zhi Xiao | Xiangya Hospital, Central-South University | Roles of neutrophil/lymphocyte ratio (NLR) in prognosis in early HER2-positive breast cancer with neuadjuvent trastuzumab and pertuzumab therapy | Roche |
8803 | Temiloluwa Prioleau | Dartmouth College | T1-DEXI Analytics | Jaeb Center for Health Research Foundation, Inc. |
8806 | Timothy Gaulton | Massachusetts General Hospital | Understanding the impact of body mass index on the effectiveness of baricitinib as a treatment for individuals hospitalized with COVID-19 | Lilly, NIAID (a data-sharing platform funded by the National Institutes of Health) |
8807 | Lena Friberg | Uppsala University | Evaluation of dose individualization strategies in optimizing survival and patient-reported outcomes of sunitinib treatment in patients with metastatic renal cell carcinoma | Pfizer |
8809 | Jing Yu | Sichuan University | Constructing a predictive model for lung cancer immunotherapy | Tempus AI, Inc. |
8815 | Rayid Abdulqawi | King Faisal Specialist Hospital and Research Centre | Effect of Calcium Channel Blocker Therapy in Idiopathic Pulmonary Fibrosis | Boehringer Ingelheim, Roche |
8828 | Christopher Moxon | University of Glasgow | Comparison of histophathology in fatal Covid-19 in Malawi with fatal cases in other settings | Hannover Medical School |
8833 | Derek Dinart | Institut Bergonié | Optimal estimation of the number of subjects in clinical trials to improve the quality of clinical research and the development of new treatments for cancer patients | Boehringer Ingelheim, Lilly, Pfizer, Roche, Sanofi |
8834 | Xiaohua Douglas Zhang | University of Kentucky | Markers derived from continuous glucose monitoring data to guide exercise for T1DM | Jaeb Center for Health Research Foundation, Inc. |
8837 | Erin Tallon | Children's Mercy Kansas City | Development of an mHealth-Based Just-In-Time Adaptive Intervention (JITAI) for Promoting Physical Activity in Individuals with Type 1 Diabetes | Jaeb Center for Health Research Foundation, Inc. |
8839 | Florencia Tettamanti | AstraZeneca | Predicting survival in chronic lymphocytic leukaemia from measurable residual disease (MRD) kinetics | Roche |
8842 | Sheng Luo | Duke University | Clinical and molecular characteristics of hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer a meta-analysis | AstraZeneca, Pfizer, Roche |
8845 | Shenghong Zhang | The first affiliated hospital of Sun Yat-sen University | Biomarkers for predicting long-term outcomes in ulcerative colitis | AbbVie, Johnson & Johnson, Takeda |
8846 | Charles Horsburgh | Boston University School of Public Health | Predictors of emergence of drug resistance while on treatment for multidrug-resistant tuberculosis: a meta-analysis | Otsuka Pharmaceuticals |
8848 | Wenrui Hao | Penn State University | Develop a mathematical model for Alzheimer's disease treatment study. | Lilly |
8850 | Changsheng Ma | Beijing Anzhen Hospital | The impact of malnutrition on the Efficacy and Safety of empagliflozin for heart failure With reduced ejection fraction | Boehringer Ingelheim |
8853 | Guang Sheng Ling | University of Hong Kong | Using clinical characteristics of hepatocellular carcinoma (HCC) patients as predictors of their immunotherapy response | Roche |
8856 | Fei Ma | Peking Union Medical College | The impact of human epidermal growth factor receptor 2-low (HER2-low) Expression on the Efficacy of endocrine therapy in Hormone Receptor-positiveHER2-Negative (HR+HER2-) Breast Cancer | AstraZeneca, Pfizer, Project Data Sphere, Roche, Sanofi |
8857 | Zachary Epstein-Peterson | Memorial Sloan Kettering Cancer Center | A phase 2 study of Cerdulatinib in treating Cutaneous T-cell Lymphomas (CTCL) | AstraZeneca |
8860 | Yutaka Shimazu | Kyoto University Hospital | Pretreatment lymphocyte counts and free light chain ratio predict the efficacy of elotuzumab against relapsed refractory multiple myeloma | Bristol Myers Squibb |
8864 | Lisa Chow | University of Minnesota | Machine Learning to evaluate glycemic variation with exercise | Jaeb Center for Health Research Foundation, Inc. |
8865 | Erin Tallon | Children’s Mercy Kansas City | Data driven approaches to inform the development of eating behavior patterns that promote glycemic management in youth with type 1 diabetes | Jaeb Center for Health Research Foundation, Inc. |
8873 | Cristina Soguero Ruiz | King Juan Carlos University | Multimodal data-driven analysis of T1D in pediatrics and adults with machine learning | Jaeb Center for Health Research Foundation, Inc. |
8874 | Nicola Dalbeth | University of Auckland | An investigation of remission in patients with gout - efficacy of treatments, prediction of remission and outcomes | Takeda |
8877 | Cinzia Del Giovane | University Hospital of Modena and Reggio Emilia | Antithrombotic therapies for secondary prevention in patients with cryptogenic stroke a systematic review and network meta-analysis with individual participant data | Boehringer Ingelheim, Daiichi Sankyo |
8879 | Micaela Morettini | Università Poiltecnica delle Marche | Development of a decision support solution to prevent hypoglycemia during and after exercise in T1D | Jaeb Center for Health Research Foundation, Inc. |
8884 | Haotian Zou | Duke University School of Medicine | Risk stratification model for predicting risk of recurrence in human epidermal growth factor receptor 2 (HER2) positive breast cancer patients with pathological complete response after neoadjuvant therapy | Roche |
8885 | Giacomo Cappon | University of Padova | ReplayBG-E: Expansion of the ReplayBG software to assess exercise-aware treatments of type 1 diabetes | Jaeb Center for Health Research Foundation, Inc. |
8889 | Fabricio Garelli | National University of La Plata | Modelling short and long-term exercise effect on glucose levels from wearable devices’ signal patterns | Jaeb Center for Health Research Foundation, Inc. |
8890 | Konrad Mulrennan | Atlantic Technological University | DEXTER - Diabetes Exercise Training for Enhanced Regulation | Jaeb Center for Health Research Foundation, Inc. |
8893 | Eleonora Manzoni | University of Padova | Detection and prediction of physical activity in type 1 diabetic subjects. | Jaeb Center for Health Research Foundation, Inc. |
8896 | Bin Cao | China-Japan Friendship Hospital | Treatment of baloxavir marboxil in immunocompromised patients with influenza infection | Roche |
8897 | Rebecca Dean | University of Sussex | The impact of interventions for depression on self-perceptions in young people: A systematic review and meta-analysis | GlaxoSmithKline |
8903 | Daniel DeSalvo | Baylor College of Medicine | A Counterfactual Data-Driven Approach to Carbohydrate Intake with Exercise in T1D: a Novel Application for Optimizing Time-In-Range | Jaeb Center for Health Research Foundation, Inc. |
8913 | Thomas Hawke | McMaster University | T1-DEXi-T Study: Does exercise training improve the time in range following acute bouts of exercise? | Jaeb Center for Health Research Foundation, Inc. |
8921 | Hongliang Liu | Duke University | The efficacy of programmed cell death protein 1 (PD-1)programmed death-ligand 1 (PD-L1) inhibitors in solid tumor patients with different clinicopathological characteristics a meta-analysis | Daiichi Sankyo, Inc., Roche |
8922 | Tomas Koutny | University of West Bohemia | In-Silico modelling | Jaeb Center for Health Research Foundation, Inc. |
8924 | Prajakta Belsare | Dartmouth College | Analyzing exercise settings and the impact of various intensities, durations, and types of exercise on people with Type 1 diabetes. | Jaeb Center for Health Research Foundation, Inc. |
8926 | Alessio Cortellini | Imperial College London | The putative differential impact of opioids exposure in patients with advanced non-small cell lung cancer (NSCLC) treated with immunotherapy or chemotherapy: a post-hoc analysis of the randomized phase 2 POPLAR and phase 3 OAK trials. | Roche |
8933 | João Pedro Ferreira | University of Porto | Non cardiovascular hospitalizations in heart failure and preserved ejection fraction (HFpEF) and the effect of empagliflozin | Boehringer Ingelheim |
8937, 6024 | Cosima Locher | University Hospital Zurich | Predictors of placebo response in opioid trials for patients with Chronic Primary Pain – An individual-patient data meta-analysis
| AbbVie, Pfizer |
8944 | Wesley Kerr | University of Pittsburgh | Evaluation of Time to Event endpoints in randomized controlled trials of multiple antiseizure medications for uncontrolled epilepsy | GlaxoSmithKline, Johnson & Johnson, UCB |
8946 | Stuart Pocock | London School of Hygiene and Tropical Medicine | Patterns of heart failure hospitalisations and cardiovascular death in EMPEROR studies | Boehringer Ingelheim |
8953 | Wilson Lin | Santa Clara University | Drivers of Algorithm/Technology Use In Type 1 Diabetes Self-Management | Jaeb Center for Health Research Foundation, Inc. |
8956 | Sheng Luo | Duke University | A Novel Machine Learning-Based Prediction Model for Outcomes in Patients with Untreated Diffuse Large B Cell Lymphoma | Project Data Sphere, Roche |
8957 | Dean Bodenham | Imperial College London | Two-sample testing for clinical trials data with missing values | Bayer |
8966 | Alberico L. Catapano | IRCCS MultiMedica | Effect of lipid-lowering therapies on lipoprotein(a) levels: a meta-analysis of randomized controlled trials | Sanofi |
8985 | Joel Skaistis | Corewell Health | Effect of tafamidis treatment on total cardiovascular and cerebrovascular events in Transthyretin (TTR) cardiac amyloidosis | Pfizer |
8997 | Lewis Carpenter | Arcturis | The integration of clinical trial data, real-world evidence, and novel statistical methods to optimise control arm recruitment in relapsed and refractory multiple myeloma | Sanofi |
9004 | Limin Zhao | Nan Chang University | Exploring the relationship between paboxib treatment and age-related gene expression differences in breast cancer patients | Pfizer |
9007 | Zhao Xingwang | Jilin University | Prediction of hypoglycemia during and after exercise | Jaeb Center for Health Research Foundation, Inc. |
9012 | Barry Greenberg | University of California, San Diego | Development of a Machine Learning Score to Predict Risk of Sudden Cardiac Death in Patients with Heart Failure with Preserved Ejection Fraction | Boehringer Ingelheim |
9016 | Alane Izu | WITS-VIDA | Evaluation of Immune Response of 10-valent Pneumococcal Conjugate Vaccine (PCV-10) in HIV infected and uninfected children | GlaxoSmithKline |
9018 | Alessio Cortellini | Imperial College London (UK) | Differential effect of systemic antibiotics and proton pump inhibitors on clinical outcomes from immunotherapy or placebo as sequential therapy in patients with locally advanced, unresectable non-small cell lung cancer (stage III) who have not progressed following chemoradiation therapy A post-hoc analysis of the PACIFIC trial | AstraZeneca |
9019 | Philip Johnson | University of Liverpool | Assessing the validity of progression free survival in patients with hepatocellular carcinoma as an endpoint in clinical trials | AbbVie, Boehringer Ingelheim, GlaxoSmithKline, Roche, Sanofi |
9024 | Alain Amstutz | University Hospital Basel | Effectiveness and safety of janus kinase inhibitors in hospitalized patients with COVID-19: Systematic review and individual patient data meta-analysis of randomized trials | IDDO, Lilly, NIAID |
9053 | Johanna Elin Gehin | Oslo University Hospital | Personalised dosing of certolizumab pegol based on serum concentration in rheumatoid arthritis patients | UCB |
9076 | Alexander Tolmach | MakeSense Digital Health Ltd. | Automatic nutrition assessment based on continuous glucose and insulin data for improvement of carbs counting and investigation of glycemia episodes | Jaeb Center for Health Research Foundation, Inc. |
9077 | Anne-Marie Wills | Massachusetts General Hospital | Predictors of Progressive Supranuclear Palsy (PSP) disease progression using “A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)” (ClinicalTrials.gov ID NCT02985879) | AbbVie |
9081 | Kyle Greenway | McGill University | Antidepressant effects of bupropion, varenicline, nicotine replacement therapy, and placebo in tobacco users. | Pfizer |
9090 | Lena Friberg | Uppsala University | Dose-exposure-response relationships for ceftazidime-avibactam of value to explore dose individualization strategies | Pfizer |
9093 | Ewan Goligher | University of Toronto | Secondary analysis for estimating heterogeneous treatment effects for the “Drotrecogin Alfa (Activated) in Adults with Septic Shock” trial | Lilly |
9098 | Stéphane Oudard | Assitance Publique des Hôpitaux de Paris | External validation of a prognostic score for survival in patients with metastatic castration-resistant prostate cancer (CABASCORE) treated with Cabazitaxel. | Sanofi |
9102 | Joel Skaistis | Corewell Health East | Effect of Tafamidis Across the Range of Systolic Function: A Post-Hoc Analysis of the ATTR-ACT Trial | Pfizer |
9103 | JOSE GARCIA-TIRADO | University of Bern | Automatic Recognition of Main Glycemic Disturbances in Type 1 Diabetes (T1D) | Jaeb Center for Health Research Foundation, Inc. |
9104 | Mark Woodward | January AI | Improving Blood Glucose Predictions for Patients with Type 1 Diabetes | Jaeb Center for Health Research Foundation, Inc. |
9105 | Nate Kowahl | Verily Life Sciences | Verily Analysis of Jaeb data | Jaeb Center for Health Research Foundation, Inc. |
9106 | Nima Aghaeepour | Stanford University | Identifying Subgroups of Patients with Improved Outcomes in Clinical Trials | AbbVie, AstraZeneca, Daiichi Sankyo, Duke, Lilly, Pfizer, Roche, Sanofi, Takeda |
9121 | Vitalay Fomin | Y-AI inc. | Biomarkers associated with response to monotherapy compared to combination therapy in cancers | Roche |
9128 | Pierluigi Navarra | Catholic University Medical School | A comparison between the assessments of overall response rate carried out by local assessors and a blinded independent central review in oncology trials. Analysis of differences in the assessment conducted at single-patient level. | Roche |
9129 | Yi-Wen Tsai | National Yang Ming Chiao Tung University | Cost-effectiveness analysis of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma subgroup analyses | Roche |
9130, 6488 | Feng Sun | Peking University | An individual participant data meta-analysis to evaluate new hypoglycemic drugs (SGLT-2i and DPP-4i) on type 2 diabetes mellitus patient sub-groups | Boehringer Ingelheim, Takeda |
9132 | Viola Pongratz | Technical University Munich | Monitoring of upper extremity motor function in Multiple Sclerosis the nine-hole-peg-test in MS revisited | Biogen, Roche, Sanofi |
9137 | Ly-Mee Yu | University of Oxford | Loop Diuretics and Weight Change in Heart Failure A Meta-Analysis | Bayer, Boehringer Ingelheim, GlaxoSmithKline |
9141 | Shujie Yang | University of Iowa | Fatty Acid Metabolism, Oxidative phosphorylation, and cholesterol homeostasis pathways in endometrial cancer organoids | Tempus AI, Inc. |
9229 | Andreas Meid | Heidelberg University Hospital | MAGIC-BULLET - Model-based support of translational steps throughout drug development of antibody-drug conjugates (ADCs) in breast cancer | Daiichi Sankyo, Roche |
9230 | Erinne Wasalski | Rutgers University | Health-Related Quality of Life in Breast Cancer Clinical Trials Through the Lens of Race and Ethnicity: The Importance of Understanding the Patient Experience | AstraZeneca, Daiichi Sankyo, Lilly, Pfizer, Roche |
9234 | Matthew Chersich | Wits Reproductive Health Institute at University of the Witwatersrand | Developing data science solutions to mitigate the health impacts of climate change in Africa: The Heat and Health African Transdisciplinary Center (HE²AT Center) | Boehringer Ingelheim, Sanofi |
9235 | Christian Lood | University of Washington | Neutrophil Lymphocyte Ratio as predictor of treatment response in malignancy | Lilly |
9236 | Christian Dansereau | Perceiv AI | Validation of prognostic machine learning tools for forecasting clinical progression to enrich Alzheimer’s disease trials | AbbVie, Lilly, Takeda |
9240 | Michael Kreissl | University Hospital Magdeburg | Parameters of Body Composition as prognostic biomarkers in patients with RET-altered thyroid cancer treated with selpercatinib Post-hoc analysis of the LIBRETTO-001 trial | Lilly |
9241 | Amit Garg | Northwell Health | Association between skin-related quality of life and race in patients with hidradenitis suppurativa, and Repeatability/Intra-rater agreement of lesion counts in hidradenitis suppurativa | AbbVie |
9244 | Kazuki Takada | Saiseikai Fukuoka General Hospital, Fukuoka, Japan | Impact of Probiotics on Clinical Outcomes in Patients with Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Atezolizumab Combination Therapy A Post Hoc Analysis of IMpower133 | Roche |
9247 | Giovanni Sebastiani | Italian National Council of Research, Institute for Applied Mathematics "Mauro Picone" | Hypoglicaemic events risk prediction for type 1 diabetes subjects during physical activity | Jaeb Center for Health Research Foundation, Inc. |
9252 | Danny Volkaerts | University Colleges Leuven-Limburg | Developing a personalized, data-driven diabetes application which assists persons with type 1 diabetes before and during physical activity regarding insulin administration and carbohydrate intake. | Jaeb Center for Health Research Foundation, Inc. |
9253 | Jiajun Yan | McMaster University | Statistical Methods for Analyzing EuroQol 5 Dimension 5 (EQ-5D) in Randomized Clinical Trials | AbbVie, Biogen, Lilly, Pfizer, Sanofi, Takeda |
9274 | Kazuki Takada | Saiseikai Fukuoka General Hospital, Fukuoka, Japan | Prognostic Impact of Probiotic Supplementation on the Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with First-Line Atezolizumab Pooled Analyses of Five Randomized Control Trials | Roche |
9275 | Kazuki Takada | Saiseikai Fukuoka General Hospital, Fukuoka, Japan | Influence of Acetaminophen on Treatment Outcomes in Advanced Non-Small Cell Lung Cancer Pooled Data Analyses from Five Randomized Control Trials of First-Line Atezolizumab | Roche |
9280 | Nuno Filipe de Sousa Vale | University of Porto | Population Pharmacokinetic Study involving different formulations of Salbutamol | GlaxoSmithKline |
9284 | Jiro McKinnis | Virror Health | Associative Analysis of Comorbidities and Clinical Variables with Concomitant Presence of CHF in Patients Undergoing Cardiac Catheterization. | Duke University School of Medicine/Duke University Hospital |
9285 | Mengyi Lu | Nanjing Medical University | Association of Body Mass Index (BMI) with Prognosis and Safety Profile of Atezolizumab | Roche |
9286 | João Sérgio Neves | Faculdade de Medicina da Universidade do Porto | Effect of Exenatide Across the Spectrum of Ejection Fraction: An analysis from the EXSCEL trial | AstraZeneca |
9328 | Sebastian Polak | Jagiellonian University Medical College in Poland | Developing a quantitative base for more effective and individualized ropinirole dosing regimen | GlaxoSmithKline |
9332 | Neeraj Narula | Hamilton Health Sciences | Outcomes from Induction Using Ustekinumab or Vedolizumab Among Patients Who Have Prior Biologic Intolerance vs Biologic Failure in Ulcerative colitis and Crohn's disease | Johnson & Johnson, Takeda |
9350 | Lucy Vivash | Monash University | Evaluation of epilepsy-DOOR (Desirability of outcome ranking) as an outcome measure for therapeutic trials in drug resistant epilepsy | UCB |
9352 | Sangwoo Kim | Yonsei University | Conventional genomic predictive markers to immune checkpoint inhibitors are deteriorated in metastatic clear cell renal cell carcinoma | Bristol Myers Squibb |
9354 | Li-Xuan Qin | Memorial Sloan Kettering Cancer Center | Tumor Mutational Burden (TMB) Dichotomization for Immunotherapy Outcome Prediction | Tempus AI, Inc. |
9360 | Guilherme Polanczyk | University of Sao Paulo (USP) | Moderators of treatment response to stimulants in preschoolers with attention-deficithyperactivity disorder an individual patient data meta-analysis | Takeda |
9373 | Amit Etkin | Alto Neuroscience, Inc. | Cognitive factors as predictors of treatment outcomes in patients with Schizophrenia | Boehringer Ingelheim |
9377 | Benjamin Haibe-Kains | University Health Network | Biomarker discovery for immunotherapy response via pan-cancer and cancer-specific analyses | Bristol Myers Squibb |
9383 | João Pedro Ferreira | Faculty of Medicine of Porto University | Anemia and the Effect of Empagliflozin in Heart Failure with Preserved Ejection Fraction (HFpEF) findings from EMPEROR-Preserved | Boehringer Ingelheim |
9384 | Evyn Peters | University Of Saskatchewan | Episode duration and severity as predictors of response to desvenlafaxine and placebo in patients with major depressive disorder | Pfizer |
9388 | Ritu Lal | GEn1E Lifesciences Inc. | A Prospective Machine Learning Model for the Identification of Sepsis Endotypes | Lilly |
9389 | Sinbad Xia | Zhejiang University School of Medicine | Predictors of survival in patients with extensive-stage small-cell lung cancer | Roche |
9390 | Joseph Merola | The International Dermatology Outcome Measures Group (IDEOM) | Musculoskeletal Symptoms in Hidradenitis Suppurativa | AbbVie |
9399 | Philip Johnson | University of Liverpool | A novel, evidence-based approach to clinical trial design in patients with advanced liver cancer (hepatocellular carcinoma); single arm studies with a virtual control group | Bayer, Boehringer Ingelheim, GlaxoSmithKline, Roche, Sanofi |
9407 | Josep Vehi | University of Girona | Validation of New Exercise Models and Therapy Optimization | Jaeb Center for Health Research Foundation, Inc. |
9410 | Abhinav Sharma | The Research Institute of the McGill University Health Centre | Proprotein convertase subtilisin/kexin type 9 (PCSK9) Inhibitors on Cardiovascular and Heart Failure Outcomes | Pfizer |
9417 | Vipul Jairath | Alimentiv Inc. | Determining Endoscopic Treatment Response in Ulcerative Colitis and Crohn’s Disease using the Win Probability Approach | AbbVie, Johnson & Johnson, Pfizer, Takeda |
9422 | James Salsbury | University of Sheffield | Developing methodology for a delayed treatment effect present in a survival trial | Bristol Myers Squibb, Roche |
9433 | Yang Li | School of Statistics, Renmin University of China | A new Statistical method to balance Social Network Effect and Covariate Effect in Response Adaptive Design | GlaxoSmithKline |
9434 | Victor Moreno | START Madrid-Fundacion Jimenez Diaz (FJD) | Retrospective analysis of different doses of atezolizumab in patients with advanced solid tumors | Roche |
9462 | Chandra Kanth Nagesh | University of Colorado Boulder | Analysis-of-Type-1-Diabetes | Jaeb Center for Health Research Foundation, Inc. |
9470 | Joseph Cafazzo | Toronto General Hospitable Research Institute, University Health Network | Can we trust GPT-4 Turbo Vision to estimate carbohydrate and caloric content from food images within the broad context of diabetes? | Jaeb Center for Health Research Foundation, Inc. |
9474 | Daniel Adam Blanco | Inari Medical, Inc. | Comparative Analysis of Health-Related Quality of Life in Pulmonary Embolism Survivors: Pulmonary Embolism Quality of Life Questionnaire (PEmb-QoL) versus EuroQol five-dimension questionnaire (EQ-5D) Instruments | Daiichi Sankyo, Inc. |
9478 | Lena Friberg | Uppsala University | Study on impact of scanning intervals of follow up tumor assessments on Progression Free Survival (PFS) and median PFS for Non-Small Cell Lung Cancer (NSCLC) patients treated with Atezolizumab and Docetaxel | Roche |
9480, 6629 | Jian-Guo Zhou | The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers and patient reported outcomes(PROs) as dynamic predictors to identify efficacy and safety of non–small-cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) | AstraZeneca, Lilly, Roche |
9481 | Nathalie Germain | Universite Laval | Melatonin and melatonin receptor agonists for the treatment of sleep disturbances associated with neurocognitive disorders | Takeda |
9492, 8697 | David McAllister | University of Glasgow | Understanding frailty, multimorbidity and renal failure in clinical trials Attrition, retention and heterogeneity of treatment effects in trials for diabetes, cancer and a heterogenous set of index conditions | AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, Lilly, Roche, Sanofi, Takeda, UCB |
9731, 7826 | Carl Turesson | Lund University | Efficacy and safety of tumor necrosis factor inhibitors (TNFi) in seronegative rheumatoid arthritis patients who are inadequate responders to conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs). A systematic literature review with meta-analysis. | AbbVie, Johnson & Johnson, Lilly, Pfizer, Roche, UCB |
9734 | James Brorson | The University of Chicago | Merging data from acute stroke secondary prevention trials for analysis of stroke recurrence risks | AstraZeneca |
9735 | Edouard Auclin | Assistance Publique des Hôpitaux de Paris | Prognostic and predictive value of the lung immune prognostic index in patients with advanced small cell lung cancers treated with immune checkpoint inhibitors | AstraZeneca, Roche |
9738 | Onyekachukwu Illoh | University of Maryland | Translating Causal Inferences from Randomized and Single-Arm Trials to Externally-Controlled Trials | Boehringer Ingelheim |
9739 | David Auerbach | SUNY Upstate Medical University | Assessment of cardiac electrical function and prevalence of electrocardiographic abnormalities in patients diagnosed with Dravet Syndrome and Lennox-Gastaut Syndrome | UCB |
9743 | Howard Scher | Memorial Sloan Kettering Cancer Center | Evaluating the association between radiographic progression free survival and overall survival using the ELMPC4 and ELMPC5 randomized clinical trial data | Takeda |
9746 | María Elena Hernando Pérez | Universidad Politécnica de Madrid | PROPHECY: Preprandial Optimized Glucose Prediction with Objective Physical Exercise and Carbohydrate Estimation for Insulin Calculation in Do-it-Yourself Systems | Jaeb Center for Health Research Foundation, Inc. |
9748 | Ho So | The Chinese University of Hong Kong | Causal inference in restrospective rheumatoid arthritis clinical studies | AbbVie, Roche |
9764 | Wenjun Yi | The Second Xiangya Hospital of Central South University | Assessing the Efficacy of Trastuzumab Emtansine (T-DM1) in Human Epidermal Growth Factor Receptor 2 (HER2)+ Breast Cancer Across Varying Hormone Receptor Statuses | Roche |
9767 | Rohan Khera | Yale School of Medicine | A computational phenomapping approach to personalize the cardiometabolic benefits of novel glucagon-like peptide-1 receptor and glucose-dependent insulinotropic polypeptide agonists in patients with type 2 diabetes mellitus. | Lilly |
9770 | Massimo Gentile | Azienda Ospedaliera Di Cosenza | Comparison between Eloquent-3 data (arm EloPd) with real-life data | Bristol Myers Squibb |
9771 | Li Yang | Renmin University of China | Covariate selection and adaptive randomization for sequential experiments | Boehringer Ingelheim |
9774 | Aristeidis Katsanos | Hamilton Health Sciences Corporation | Individual Participant Data Meta-Analysis of Randomized Trials of Anticoagulation compared to Antiplatelet Therapy in Patients with Embolic Strokes of Undetermined Source | Boehringer Ingelheim |
9787 | Hongmei Zheng | Huazhong University of Science and Technology | Clinical and molecular characteristics of human epidermal growth factor receptor 2-positive breast cancers: a meta-analysis | Roche |
9792 | Maria Pia Sormani | University of Genoa | Defining responders to teriflunomide treatment in Multiple Sclerosis | Sanofi |
9793 | Lea Dousset | Translational Research Institute, The University of Queensland | Immunotherapy as Prophylaxis: Exploring the Potential Impact on Hyper-Chronic Non-Melanoma Skin Cancers in Retrospective Melanoma Cohorts | Bristol Myers Squibb |
9797 | Julian Stiels | OneTwenty AG | Advanced blood glucose prediction modelling | Jaeb Center for Health Research Foundation, Inc. |
9809 | Emma Fröling | Universitätsmedizin Charité Berlin | Systematic Review and Meta-Analysis of Adverse Events During Levetiracetam Therapy | UCB |
9813 | Sameer Jauhar | King’s College London | Conducting a systematic review and meta-analysis to assess the incidence and severity of withdrawal symptoms following discontinuation of antidepressants | Lilly, Lundbeck, Pfizer, Takeda |
9815 | Tim Greten | Center for Cancer Research, National Cancer Institute, NIH | Locoregional therapy impact on immunotherapy | Roche |
9817 | Marco Gerlinger | Queen Mary University of London | To determine whether Programmed Cell Death Ligand 1 (PDL1) expression in oesophago-gastric cancer differs depending on the tumour site from which the biopsy was taken from | Bristol Myers Squibb |
9821 | Richard Franzese | GlaxoSmithKline | Assessment of the predictive value of longitudinal circulating tumour deoxyribonucleic acid (ctDNA) dynamics for survival outcomes in non-small-cell lung cancer (NSCLC) | Roche |
9824 | Martin Okun | Fort HealthCare | Using Patient-Level Data from Psoriasis Clinical Trials to Evaluate the Relationship between Changes in Skin and Nail Psoriasis | Lilly |
9826 | Lorna Wheaton | University of Leicester | Development and application of new statistical methods for meta-analysis to evaluate treatment effectiveness and surrogate relationships in biomarker subgroups | AstraZeneca, Roche |
9829 | Yuanyuan Kong | Beijing Friendship Hospital | Clinical and molecular profiles of Hepatocellular Carcinoma (HCC) treated with combination immunotherapy | Roche |
9834 | Tao Han | The First Hospital of China Medical University | Clinical and molecular profiles of Hepatocellular Carcinoma (HCC) | Bayer, Boehringer Ingelheim, NIDDK Central, Roche, Sanofi |
9835 | Yuya Matsue | Juntendo University School of Medicine Graduate School of Medicine | Impact of serum hepcidin levels on the efficacy of daprodustat treatment in patients with chronic kidney disease | GlaxoSmithKline |
9841 | Anke Richters | The Netherlands Comprehensive Cancer Organisation | Estimating heterogeneous treatment effects of immunotherapy combination regimens for treatment of advanced/metastatic clear cell renal cell carcinoma: an individual patient data meta-analysis | Bristol Myers Squibb |
9844 | Mariam Khayretdinova | Brainify.AI | Predicting Placebo Response in Major Depressive Disorder on Clinical Trials Data Using Artificial Intelligence (AI)/Machine Learning (ML) | Lilly |
9845 | Yao Zhu | Fudan University Shanghai Cancer Center | Serum sodium maintenance levels and outcomes in patients with advanced prostate cancer | Bayer, Sanofi |
9846 | Samantha Kleinberg | Stevens Institute of Technology | Examining Effects of Meals on Glucose in Individuals with Type 1 Diabetes | Jaeb Center for Health Research Foundation, Inc. |
9848 | Garrett Ash | Yale School of Medicine | Developing a pre-trainable foundation time series model for blood glucose prediction among people with type 1 diabetes (T1D) and then applying it to a vulnerable, understudied subset of them | Jaeb Center for Health Research Foundation, Inc. |
9863 | Yasuhiro Hagiwara | The University of Tokyo | Development of Covariate Adjustment Methods to Improve Efficiency of Randomized Clinical Trials for human immunodeficiency virus Infected Patients | GlaxoSmithKline |
9866 | Weituo Zhang | Shanghai Jiao Tong University School of Medicine | Comparing methods of selecting and adjusting for confounding factors in clinical trial | Lilly |
9870 | Alexandre Betourne | Critical Path Institute | Integration of Biogen Choroideremia Data (NCT03359551 ; NTCNCT03496012) into the Rare Diseases Cures Accelerator Data and Analytics Platform (RDCA-DAP) | Biogen |
9890 | Jasmine Mitchell | University of California, Los Angeles | The Effect of Serotonin Reuptake Inhibitors in Metastatic Colorectal Cancer | Roche |
9906 | Alessio Cortellini | Department of Surgery and Cancer Imperial College London, London | The putative role of Proton-Pump Inhibitors in patients with Basal Cell Carcinoma treated with vismodegib | Roche |
9907 | Akihiro Hirakawa | Tokyo Medical and Dental University | Developing new statistical methodology harnessing nonconcurrent control data in infectious disease platform trials | Lilly, Montreal Heart Institute, NIAID |
9908 | Haitao Zhao | Peking Union Medical College Hospital | The clinical and prognostic features of acquired resistance to immune-checkpoint inhibitors (ICIs) in Hepatocellular carcinoma (HCC) | Roche |
9909 | John Clemmer | University of Mississippi Medical Center | Improving heart failure with preserved ejection fraction (HFpEF) treatment using a mathematical model of physiology | Boehringer Ingelheim |
9910 | Yang Li | Renmin University of China | Missing data considerations for patient reported outcome measures in randomized controlled trials | Pfizer |
9911 | Kazuki Takada | Saiseikai Fukuoka General Hospital | Prognosis of inoperable patients after preoperative atezolizumab administration: A post hoc analysis of Lung Cancer Mutation Consortium (LCMC) 3 | Roche |
9912 | Soumyajit Roy | Rush University Medical Center | Causal mediation role of prostate-specific antigen (PSA) and pain in metastatic hormone sensitive prostate cancer: a pooled analysis of 3 randomized controlled trials | Bayer, Johnson & Johnson |
9912, 9387 | Soumyajit Roy | Rush University Medical Center | Causal mediation role of prostate-specific antigen (PSA) and pain in metastatic hormone sensitive prostate cancer: a pooled analysis of 3 randomized controlled trials | Bayer, Johnson & Johnson |
9920 | Soumyajit Roy | Rush University Medical Center | Does Timing of Metastatic Presentation (Synchronous versus Asynchronous) Affect Outcome in Advanced Urothelial Carcinoma? | AstraZeneca, Lilly, Roche |
9924 | Thomas Büttner | University Hospital Bonn | Evaluation of Bellmunt Risk Score as a prognostic score in metastatic-castration resistant prostate cancer | Johnson & Johnson, Sanofi, Takeda |
9939 | Xiaoyu Yan | The Chinese University of Hong Kong | Organ specific tumor dynamic predict survival in patients with metastatic breast cancer | Lilly, Pfizer, Roche |
9960 | Zhengfei Zhu | Fudan University Shanghai Cancer Center | Organ-specific response to atezolizumab and radiotherapy in advanced non-small cell lung cancer patients: a pooled analysis | Roche |
9963 | Hanna Suominen | The Australian National University | Develop Type 1 Diabetes Simulators/Models for Exercise in Type 1 Diabetes | Jaeb Center for Health Research Foundation, Inc. |
9964 | João Sérgio Neves | Universidade do Porto | Effects of tirzepatide versus semaglutide on cardiovascular risk in patients with type 2 diabetes | Lilly |
10028 | Hanne Vanluchene | AZ Delta | Development of an Inflammatory Bowel Disease (IBD) patient population dashboard to monitor and improve care through machine learning | AbbVie, Johnson & Johnson |
10030 | Lihi Eder | Women's College Hospital | Exploring Sex-related Mechanisms of Psoriatic Arthritis (PSA) response to advanced therapies (EXSEMP): Individual participant data (IPD) meta-analysis of randomized controlled trials of advanced therapies | AbbVie, Johnson & Johnson, Lilly, Pfizer |
10032 | Shenghong Zhang | The First Affiliated Hospital of Sun Yat-Sen University | Dynamics of Disease Activity in Monitoring Therapeutic Outcomes and Predicting Prognosis for Ulcerative Colitis | Johnson & Johnson, Takeda |
10036 | Akihiro Hirakawa | Tokyo Medical and Dental University | Development of statistical methodology considering placebo response in randomized controlled trials targeting Alzheimer's disease | Lilly |
10037 | Shenghong Zhang | The first affiliated hospital of Sun Yat-sen University | Dynamics of Disease Activity in Monitoring Therapeutic Outcomes and Predicting Prognosis for Crohn's disease | AbbVie, Johnson & Johnson, Takeda |
10038 | Linong Ji | Peking University People’s Hospital | Identify treatment responders in patients with type 2 diabetes using a machine learning based dynamic cardiovascular risk assessment tool (ML-CVD) in clinical trials | Bayer, Johnson & Johnson, Lilly, Sanofi, Takeda |
10039, 8807 | Lena Friberg | Uppsala University | Evaluation of dose individualization strategies in optimizing survival and patient-reported outcomes of sunitinib treatment in patients with metastatic renal cell carcinoma | Pfizer |
10046 | Matthew Galsky | Icahn School of Medicine at Mount Sinai | Exploring C-reactive protein (CRP) dynamics and resistance to immunotherapy in bladder cancer | Roche |
10047 | Ramona Belfiore-Oshan | Critical Path Institute | Bayesian item response theory model for the North Star Ambulatory Assessment (NSAA) rating scale | CureDuchenne |
10049 | Dag Aarsland | King’s College London | Neutrophil to Lymphocyte Ratio Decrease and Its Association with Clinical Changes in Late-Life Depression Treated with Vortioxetine (Lu AA21004) | Lundbeck |
10052 | Yasuhiro Hagiwara | The University of Tokyo | Adjusting for treatment switching in Oncology Trials: Sensitivity Analysis for Rank-Preserving Structural Failure Time Model | Pfizer, Roche |
10054 | Lisa Koch | University of Bern | Foundational machine learning models for large scale robust modelling of continuous glucose monitoring and activity data | Jaeb Center for Health Research Foundation, Inc. |
10055 | Christian Torp-Peteresen | North Zealand Hospital | Reanalyzing Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPAREG) using Longitudinal Targeted Maximum Likelihood Estimation (LTMLE) analysis | Boehringer Ingelheim |
10090 | David Baker | Queen Mary University of London | Monitoring white blood cells as an indicator to assess the risks of treatment failure in multiple sclerosis | Biogen |
10091 | Jonas Saal | University Hospital Bonn | Establishing a risk score for Skeletal Related Events (SRE) in patients with cancer | Bayer, Johnson & Johnson, Project Data Sphere, Sanofi |
10094 | Sabatina Criscuolo | University of Naples Federico II | Machine Learning approach for glycemia prediction in type 1 diabetes | Jaeb Center for Health Research Foundation, Inc. |
10095 | Michael Greicius | Stanford University | Repurposing clinical trial data to understand potential effects of functional unblinding on outcome measures in Gantenerumab trials | Roche |
10106 | Mehmet Fatih Ozbay | Kirsehir Training and Research Hospital | Exploring the Correlation between Programmed Death-Ligand 1 (PD-L1) Levels and Eosinophilia in Advanced Lung Cancer Patients Treated with Atezolizumab | Roche |
10112 | Alessio Cortellini | Imperial College London | TP53 missense and truncating mutations may be linked to differential response to checkpoint blockade in patients with advanced non-small cell lung cancer: a post hoc analysis of the OAK and POPLAR trials | Roche |
10116 | Jean-Pierre Fauvel | University Claude Bernard Lyon 1 | Development and validation of clinical prediction tools to estimate all-cause mortality, cardiovascular and renal risk in non-dialysis chronic kidney disease (CKD) patients using machine learning | GlaxoSmithKline |
10118 | Neeraj Narula | Hamilton Health Sciences | Assessing Outcomes from the EXTEND Clinical Trial Using the Modified Multiplier of the Simple Endoscopic Score for Crohn's disease (MM-SES-CD) | AbbVie |
10120 | Pablo Bonangelino | US Food and Drug Administration | A Bayesian borrowing-by-parts method integrated with propensity score stratification for borrowing adult data for pediatrics | GlaxoSmithKline |
10121 | Itsuki Osawa | Columbia University Irving Medical Center | Optimized timing of empagliflozin use for cardiorenal protection: a post-hoc analysis of the EMPA-REG OUTCOME, EMPEROR-REDUCED, and EMPEROR-PRESERVED clinical trials | Boehringer Ingelheim |
10126 | Wataru Fukuokaya | The Jikei University School of Medicine | Heterogeneous treatment effects of cabazitaxel in patients with castration-resistant prostate cancer | Sanofi |
10138 | Issa Dahabreh | Harvard T.H. Chan School of Public Health | Development of statistical methods for comparison of the efficacy of anticoagulants in non-valvular atrial fibrillation | Boehringer Ingelheim, Daiichi Sankyo |
10146 | Yuki Miyai | Nagoya University Hospital | Impact of Body Mass Index on Survival and Response in Cancer Patients Treated with Immune Checkpoint Inhibitors | AstraZeneca, ONO, Project Data Sphere, Roche |
10155 | Brian Gillette | Droice Labs | Developing approaches to accelerate clinical trials using real world data (RWD) from electronic health records (EHR) | Daiichi Sankyo, Lilly, Takeda |
10158 | Si-Cong Ma | The First Affiliated Hospital of Sun Yat-Sen University | Biomarker-based strategies to enhance efficacy and reduce toxicity in lung cancer immunotherapy | Roche |
10204 | Yanguang Cao | University of North Carolina at Chapel Hill | Identifying Prognostic and Predictive Factors for Causal Exposure-Response Analysis of Imatinib in Treatment of Chronic Myeloid Leukemia | Pfizer, Takeda |
10290 | Jeffrey Bower | Sana Health, Inc. | Anchor Based Minimal Clinical Important Difference Calculation for the Neuropathic Pain Inventory Scale | Pfizer |
10293 | Joao Pedro Ferreira | Porto University | Effect of Empagliflozin on Blood Pressure in Acute Heart Failure | Boehringer Ingelheim |
10313 | Linsen Ye | The Third Affiliated Hospital, Sun Yat-Sen University | Effect of liver lipid deposition on the treatment of atezolizumab plus bevacizumab: a retrospective study based on the IMBrave150 | Roche |
10317 | Kelley Kidwell | University of Michigan School of Public Health | Seamless Design for Multiple Endpoints for Drug Development in Rare Diseases Using Gaussian Copula Model in Bayesian Framework : a case study from Hunter syndrome | Takeda |
10341 | Neeraj Narula | Hamilton Health Sciences | Comparison of Onset of Efficacy of Therapies for Ulcerative Colitis Based on Patient Symptom Diary Data | AbbVie, Johnson & Johnson, Lilly, Takeda |
10360 | Javier Calvo | Universidad de Costa Rica | Identifying Clinical Predictors of Weight Loss in Older Adults with Diabetes: Insights from SURPASS Clinical Trials | Lilly |
10381 | Neeraj Narula | Hamilton Health Sciences | Impact of Concomitant Steroid Use on Adverse Events in Ulcerative Colitis Clinical Trials | AbbVie, Johnson & Johnson, Pfizer, Takeda |
10391 | You-Shan Feng | Universitätsklinikum Tübingen | Psychometric properties and scoring approaches for the EuroQol-5 dimension-5 level (EQ-5D-5L) Psoriasis-specific questions | Lilly |
10403 | Ignacio Leiva-Escobar | Heidelberg University Hospital | TREND-REVIVAL – Trial result extension and disease course modelling to real world evidence generation in multiple myeloma | Project Data Sphere, Takeda |
10406 | Toby Pillinger | King's College London | Physiological effects of acute antidepressant treatment in psychiatric disorders: a systematic review and network meta-analysis | GlaxoSmithKline, Lilly, Lundbeck, Pfizer, Takeda |
10408 | Su Syonmez | Orchard Therapeutics | Natural History Study of Patients With Mucopolysaccharidosis type IIIA (MPS IIIA) | Takeda |
10411 | Joao Pedro Ferreira | Porto University | Non-steroidal anti-inflammatory drugs (NSAIDs) use and kidney outcomes in Heart Failure | Boehringer Ingelheim |
10443 | Vitalay Fomin | YAI, Inc. | 2024 DataWorks! Prize: Analyzing COVID-19 Drug Approval and Patient Response Using Historical Data | Certara, Hannover Medical School, HCor Research Institute, Hospital Universitario Australia, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Johns Hopkins University,
Montreal Heart Institute, Salix Pharmaceuticals, University of Alabama at Birmingham, University of Minnesota, University of Washington, Wits Health Consortium |
10450 | Sam Royston | Replica Health | Merging Big Datasets for Training Blood Glucose Prediction Models | Jaeb Center for Health Research Foundation, Inc. |
10462 | Nermin Diab | McMaster University | Efficacy and safety of monoclonal antibodies in patients with uncontrolled asthma: a systematic review and network meta-analysis | GlaxoSmithKline, ImmPort, Johnson & Johnson |
10464 | Maria Panagiotou | University of Bern | Blood Glucose Prediction | Jaeb Center for Health Research Foundation, Inc. |
10466 | Mia Jovanova | University of St. Gallen | Temporal dynamics of lifestyle factors and glycemic control among children with Type-1 Diabetes | Jaeb Center for Health Research Foundation, Inc. |
10469 | Shenghong Zhang | The first affiliated hospital of Sun Yat-sen University | Predictors and prediction model for therapeutic outcomes in patients with ulcerative colitis receiving Mirikizumab | Lilly |
10471 | Khandan Keyomarsi | The University of Texas MD Anderson Cancer Center | Validation of Predictive Molecular Biomarker for Predicting Response to Cyclin-Dependent Kinase 4 and 6 (CDK4/6) Inhibitors in Breast Cancer Using Data from PALOMA-2 and PALOMA-3 Studies | Pfizer |
10475 | Jiabin Cai | Zhongshan Hospital | Clinical and Molecular Characterization of Advanced Hepatocellular Carcinoma: Analysis of Therapeutic Responses Across Multiple Treatment Regimens | Bayer, ImmPort, Project Data Sphere, Sanofi |
10492 | Yongwen Zhou | The Third Affiliated Hospital of SYSU | Reinforcement learning for personlized automated insulin delivery system among type 1 diabetes | Jaeb Center for Health Research Foundation, Inc. |
10511 | Min Hyuk Lim | UNIST (Ulsan National Institute of Science and Technology) | A study of establishing Machine Learning (ML) and Artificial Intelligence (AI) models for glucose dynamics | Jaeb Center for Health Research Foundation, Inc. |
10549 | Sumayyah Patel | University of Leeds | Cognition in Multiple Myeloma: A Systematic Review and Meta-Analysis | Takeda |
10706 | Neeraj Narula | Hamilton Health Sciences | Assessing the Impact of Disease Duration on the Likelihood of Healing in the Ileum and Colon in Crohn’s Disease | AbbVie, Johnson & Johnson, Takeda |
10732 | Bryan Saunders | University of Sao Paulo | Semaglutide for weight loss: Where is the weight loss coming from? A systematic review and meta-analysis | Lilly |
10735 | Andrew Achaiah | Gloucestershire Royal Hospital, Gloucestershire Hospitals NHS Foundation Trust | Exploration of change in forced expiratory volume:forced vital capacity (FEV1:FVC) ratio from baseline to prognosticate clinical outcomes in idiopathic pulmonary fibrosis and predict treatment response to Nintedanib | Boehringer Ingelheim |
10749 | Dennis Shung | Yale School of Medicine | DT1D: Digital Twin for Type 1 Diabetes | Jaeb Center for Health Research Foundation, Inc. |
10752 | Anna Maria Claudia Wagner | Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FCIISC) | Exercise in type 1 diabetes | Jaeb Center for Health Research Foundation, Inc. |
10783 | Kathryn Connelly | Monash University School of Clinical Sciences | Can a core set of disease activity domains define response in systemic lupus erythematosus clinical trials? An analysis of two Phase 3 randomised controlled trials of belimumab | GlaxoSmithKline |
10832 | Jay Park | Core Clinical Sciences | Assessing the Potential Effect of a New Diabetes Treatment in Canadian Populations | Lilly |
10852 | Ramona Belfiore-Oshan | Critical Path Institute | Development of an Artificial Intelligence/Machine Learning (AI/ML) model-based clinical trial simulation platform to better characterize Loss of Ambulation in Duchenne Muscular Dystrophy (DMD) | CureDuchenne |